



## Review article

# Strategies for elevating hematopoietic stem cells expansion and engraftment capacity



Mehdi Derakhshani<sup>a,b</sup>, Hossein Abbaszadeh<sup>a</sup>, Ali Akbar Movassaghpour<sup>a</sup>, Amir Mehdizadeh<sup>c</sup>, Majid Ebrahimi-Warkiani<sup>d</sup>, Mehdi Yousefi<sup>e,f,g,\*</sup>

<sup>a</sup> Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>b</sup> Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>c</sup> Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>d</sup> School of Biomedical Engineering, University Technology of Sydney, Sydney, New South Wales, 2007, Australia

<sup>e</sup> Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>f</sup> Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>g</sup> Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

## ARTICLE INFO

## Keywords:

Hematopoietic stem cells  
Mesenchymal stem cells  
Microfluidic system  
Expansion

## ABSTRACT

Hematopoietic stem cells (HSCs) are a rare cell population in adult bone marrow, mobilized peripheral blood, and umbilical cord blood possessing self-renewal and differentiation capability into a full spectrum of blood cells. Bone marrow HSC transplantation has been considered as an ideal option for certain disorders treatment including hematologic diseases, leukemia, immunodeficiency, bone marrow failure syndrome, genetic defects such as thalassemia, sickle cell anemia, autoimmune disease, and certain solid cancers. Ex vivo proliferation of these cells prior to transplantation has been proposed as a potential solution against limited number of stem cells. In such culture process, MSCs have also been shown to exhibit high capacity for secretion of soluble mediators contributing to the principle biological and therapeutic activities of HSCs. In addition, endothelial cells have been introduced to bridge the blood and sub tissues in the bone marrow, as well as, HSCs regeneration induction and survival. Cell culture in the laboratory environment requires cell growth strict control to protect against contamination, symmetrical cell division and optimal conditions for maximum yield. In this regard, microfluidic systems provide culture and analysis capabilities in micro volume scales. Moreover, two-dimensional cultures cannot fully demonstrate extracellular matrix found in different tissues and organs as an abstract representation of three dimensional cell structure. Microfluidic systems can also strongly describe the effects of physical factors such as temperature and pressure on cell behavior.

## 1. Introduction

Hematopoiesis is a continuous process which contributes to the production of all blood cells in the bone marrow, maintaining controlled differentiation and self-renewal features of HSCs, and the migration of mature cells into the bloodstream [1–4]. Hematopoietic stem cells (HSCs), as a rare cell population in adult Bone Marrow (BM), demonstrate a self-renewal capability and differentiation potentials into a full spectrum of blood cells. Common sources of HSCs are bone marrow, mobilized peripheral blood (MPB), and umbilical cord blood (UCB) [5]. Phenotypically, these cells show a CD34<sup>+</sup>, CD38<sup>-</sup>, CD90<sup>+</sup>, Lin<sup>-</sup>, and CD45RA<sup>-</sup> pattern as surface markers [6].

In patients lacking a human leukocyte antigen-matched marrow donor, human umbilical cord blood (HUCB) has been clinically

considered as an alternative source of HSCs for allogeneic transplantation. The main advantages of UCB over stem cells are the relatively ease of procurement, the absence of donor risk, significantly reduced risk of infection transmission, and the rapid availability of the sample [7]. Ex vivo proliferation of the cells prior to transplantation has been introduced as a potential solution for low stem cell numbers. Extensive researches have been performed to determine the optimal conditions critical for ex vivo HSCs expansion, leading to various expansion techniques development [8,9]. Human bone marrow stem cell expansion in ex vivo cultures have been reported to have significant applications in transplantation, stem cell marking, and gene therapy [10]. In this review, specific HSC expansion techniques will be discussed which presents useful data for improvement of HSC engraftment and reducing related economic burden.

\* Corresponding author at: Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

E-mail address: [Yousefime@tbzmed.ac.ir](mailto:Yousefime@tbzmed.ac.ir) (M. Yousefi).

<https://doi.org/10.1016/j.lfs.2019.116598>

Received 18 May 2019; Received in revised form 22 June 2019; Accepted 23 June 2019

Available online 25 June 2019

0024-3205/ © 2019 Elsevier Inc. All rights reserved.

## 2. Mesenchymal stem cells (MSCs)

MSCs were first identified by Alexander Friedenstein [11]. These cells can be isolated from various sources including bone marrow, peripheral and umbilical cord blood, umbilical cord tissue, amniotic fluid, adipose tissue, synovium, skin, dental pulp, placental complex, and endometrium [12,13]. In 2006, the Mesenchymal and Tissue Stem Cell Committee of International society cell and gene therapy (ISCT) proposed a set of minimal criteria in order to standardize a current working definition for MSCs. First, MSCs should be plastic-adherent when maintained in standard culture conditions. Second, MSCs must express CD105, CD73, and CD90, and lack the expression of CD45, CD34, CD14 or CD11b, CD79 or CD19, and HLA-DR surface molecules. Third, MSCs must be differentiated into osteoblasts, adipocytes, and chondrocytes, in vitro [14]. MSC requires specific conditions to differentiate into osteoblasts and chondrocyte. TGF- $\beta$  is a cytokine which inhibits MSCs differentiation into osteoblasts. In this regard, trombospondin-1(TSP-1) is essential for TGF- $\beta$  activation. Kimberly Bailey Du Bose et al. [15]. have shown that following TSP-1 inhibition, TGF- $\beta$  activation is reduced and MSCs differentiation to osteoblast is increased. TSP-1 also enhances MSCs proliferation and migration by PDGF protection against MSCs-derived protease [16]. Trombospondin-2(TSP-2) is also expressed on MSCs which exerts chondrogenic effects. TSP-2 leads to the differentiation of MSC into chondrocyte through P38MAPK, PKC, ERK and NOTCH signaling pathways [17]. The primary source of trombospondin production is mesenchymal stem cells. K.D. Hankenson et al. [18] Have shown that TSP-2 addition to MSCs derived from TSP-2 Null murine reduces proliferation of MSCs. MSCs possess high capacity for the secretion of soluble mediators, which contribute to the principle biological and therapeutic activities. MSCs secrete stromal derived factor-1 (SDF-1) [19], which plays a critical role in HSCs marrow niche homing [20]. MSCs constitutively secrete the IL-6, IL-7, IL-8, IL-11, IL-12, IL-14, IL-15, macrophage colony stimulating factor (M-CSF), Flt3 ligand, and stem cell factor (SCF), in vitro. MSCs can also be induced to further express IL-1 $\alpha$ , leukemia inhibitory factor (LIF), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) following IL-1 $\alpha$  stimulation [21]. Moreover, several chemokine ligands can also be secreted by MSCs including CCL2, CCL4, CCL5, CCL20, CX3CL1, and CXCL8 [22]. Mesenchymal cells determine HSC fate through cell-to-cell interaction and cytokine secretion, increasing HSCs self-renewal and proliferation properties [23,24]. These cells also represent immunomodulatory properties reducing the incidence of graft versus host disease (GVHD) [25].

## 3. Niche

The niche concept was first coined by Schofield in the 1978 [21]. It refers to the in vivo microenvironment of bone marrow, which provides significant prerequisite place for self-renewal, differentiation, and survival of HSCs [26]. HSCs are located within the bone marrow microenvironment or niche, which regulates the quiescence, proliferation and differentiation of these cells [27]. Chemical signals such as binding and secretive molecules and physical signals like oxygen tension, shear stress, contractile forces and temperature originated from surrounding cells can modulate the HSC features like survival, differentiation and self-renewal [3,28,29].

## 4. Perivascular niche

The bone marrow contains a vast network of sinusoidal vessels [30]. The vascular niche is in proximity to vascular endothelium. Cellular constituents of this niche are nestin<sup>+</sup> MSCs, *Lepr*-expressing perivascular stromal cells, sympathetic neurons, and CXCL12<sup>+</sup> adventitial reticular cells (CARs) in addition to endothelial cells [31–34] Fig. 1.

## 4.1. The role of the cells present in the Perivascular niche

### 4.1.1. Endothelial cells

Covering the luminal surface of the blood vessels, endothelial cells bridge the blood and sub tissues in the bone marrow, as well as, regeneration induction and HSCs survival [35,36]. Endothelial cells are not homogeneous in their morphology, gene expression, antigen composition distribution, and function [33]. These cells are surrounded with pericytes or CXCL12 adventitial reticular cells (CAR cell) including nestin + CAR cells, as specialized pericytes [37]. Endothelial cells and hematopoietic cells originate from hemangioblast as a common multi potential precursor source [38,39]. Furthermore, cultivated endothelial cells isolated from non-hematopoietic organs can also maintain stem cells [40]. These cells have been proposed to support the hematopoiesis procedure by expression of surface markers including *E*-Selectin and up-regulation of 'angiocrine' factors such as fibroblast growth factor 2 (FGF2), delta-like 1 (DLL1), insulin-like growth factor-binding protein 2 (IGFBP2), angiopoietin 1 (ANGPT1), desert hedgehog (DHH) and epidermal growth factor (EGF) [36,39,41,42].

### 4.1.2. Pericytes

Pericytes which are located in pericytic position adjacent to CAR cells, cover the wall of blood vessels [43] and can be identified by their location, as well as, surface markers such as platelet-derived growth factor receptor (PDGFR), CD146, neuron-glia 2 (NG2), SMA, desmin, and Nestin [44]. These cells are divided into sinusoidal and arterial subgroups, which can be detected in mice regarding the level of NES-GFP expression [45]. Significant reduction in HSCs number is the direct result of in vivo ablation of pericytes in bone marrow [32]. HSCs maintenance in the BM has been suggested to be regulated by leptin-receptor expressing pericytes [46].

### 4.1.3. CXCL12<sup>+</sup> adventitial reticular cells

CAR cells, closely related to a CD146<sup>+</sup> adventitial reticular cell, are associated with sinusoidal endothelium [32] and are responsible for significant roles in HSCs homing through CXCL12 production. FOXC1 transcription factor has been recently identified in CAR cells which plays an important role in HSCs maintenance, in vivo [47]. It has been reported that selective destruction of CAR cells can also reduce HSC count [31].

### 4.1.4. Nerves

The fate of HSCs can also be modulated by sympathetic nervous system producing catecholamine, which is transmitted into the bone marrow microenvironment via nerve endings or the bloodstream to induce paracrine effects on HSCs [48]. The sympathetic nervous system is not involved in HSCs number maintenance, however, they influence HSCs mobilization [33]. Adrenergic signaling contributes in reduced CXCL12 synthesis, which facilitates the HSCs mobilization into peripheral blood [34,49].


## 5. Endosteal niche

The endosteal niche is characterized by trabecular or cortical bone close position. After transplantation, the adjacent to endosteum is one of the primary sites for HSC homing [50]. The endosteal niche includes certain essential cellular components such as osteoblast, osteoclast, and Nestin<sup>+</sup> MSCs [32,51–53].

## 5.1. The role of the cells present in the Endosteal niche

### 5.1.1. Osteoblasts

Osteoblasts along with osteoclasts regulate bone formation and resorption, respectively, within the bone marrow niche where pre-osteoclasts induce osteoblasts retraction [54]. Osteoblasts support the HSCs growth and regulate their numbers [51,52]. The interactions



**Fig. 1.** Demonstration of the cells involved in HSC fate maintenance and regulation. Different cell types are involved in maintenance and regulation of HSC fate, including endothelial cells, CAR cells, nerves, pericyte cells, and mesenchymal stem cells, which control the HSC fate through production of cytokines and chemokines such as CXCL12, SCF, regulating factors (pleiotrophin, angiopoietin), and notch and WNT signaling pathways. Sympathetic nerves decrease CXCL12 production and consequently increase HSC proliferation through the released norepinephrine from nerve endings and their attachment to receptors on the HSC surface. CAR cells along with MSCs induce increased HSC homing via CXCL12 production. Pericyte cells play important role in HSC maintenance through leptin production and its attachment to leptin receptors on HSCs. By jagged and DLL production, which are the corresponding notch ligands on HSCs, endothelial cells contribute to increased HSCs proliferation. Moreover, endothelial cells induce HSC quiescence phase by angiopoietin 1 production and its attachment to Tie2. Endothelial cell and pericytes induce increased maintenance and survival of HSCs by secretion of SCF and its bonding to C-Kit on the surface of HSCs. Osteoblasts also induce quiescence phase in HSCs through Wnt production and attachment to HSC frizzles receptors. Pleiotrophin, produced by endothelial cells also induces quiescence phase in HSCs through RAS signaling pathway and activation of DMTF1 transcription factor. HSC: Hematopoietic stem cells, CAR cell: CXCL12+ adventitial reticular cells, MSC: Mesenchymal stem cell, DLL: Delta like Ligand, SCF: Stem cell factor or Kit Ligand, FZR: frizzles receptor, LepR :Leptin receptor, CXCR4: C-X-C chemokine receptor type 4, CXCL 12 : C-X-C chemokine Ligand 12.

between HSCs and N-cadherin+ osteoblasts are dependent to the stem cell quiescence regulation by Angiopoietin-1/Tie2 tyrosine kinase receptor and increase of HSC numbers through Jagged 1/Notch signaling [51,52,55]. Several studies have reported that osteoblasts are essential for stem cell number maintenance, so that, the loss of these cells results in the decreased numbers of HSCs. [51,52,56]

### 5.1.2. Osteoclasts

Osteoclasts are polykaryons derived from monocyte/macrophage lineage in the hematopoiesis process as the exclusive bone resorptive cell [57]. Bone-resorbing osteoclasts significantly contribute to stress-induced mobilization of HSCs via matrix metalloproteinase-9 (MMP-9) and CXCR4 dependent mechanisms. Defective HSC niche with decreased osteoblastic differentiation and relatively increased mesenchymal progenitor proportion has been reported in an impaired osteoblast

activity mouse model [58].

## 6. Hematopoietic stem cell expansion

Bone marrow HSC transplantation has been considered as an ideal option for certain disorders treatment including hematologic diseases, leukemia, immunodeficiency, bone marrow failure syndrome, genetic defects such as thalassemia, sickle cell anemia, autoimmune disease and certain solid tumors [59]. Either the patient's own HSCs (autologous transplant) or HSCs derived from a donor with matched human leukocyte antigen (HLA) (allograft transplant) can be used as the cell sources for transplantation [60,61]. The cells used for HSCT can be isolated from different sources such as bone marrow, umbilical cord blood, and mobilized HSCs to peripheral blood through granulocyte-colony stimulating factor (G-CSF) induction [62].

The precise balance between different cell fates (quiescence, self-renewal, differentiation, apoptosis, and migration) acts as the determinant for HSC numbers in vitro and in vivo. The number of HSCs are strictly correlated with successful engraftments, as well as patient survival. The required number for a successful transplantation is  $\geq 2.5 \times 10^7$  cell/kg human body weight [63]. Insufficient numbers of HSCs might cause impediment in successful transplantation. Extremely low frequency of HSCs in corresponding organs in some patients is a major problem along with their applications in transplantation. Therefore, HSCs must be expanded ex vivo in such cases. Moreover, the number of HSCs in umbilical cord blood is not enough for successful transplantation in adult population and they should also be expanded in vitro [64,65].

## 7. HSCs expansion strategies for transplantation

### 7.1. HSC co-culture

HSC fate can be modulated by bone marrow niche cells. In vitro HSCs culture conditions are mostly associated with differentiation or apoptosis. An increased expansion of hematopoietic cells has been observed in HSCs and different stromal cells, MSCs and endothelial cells co-culture [66–69]. Mesenchymal stem cells can improve HSC expansion by modulating cell-to-cell communications and secretory cytokine production [70–72]. It has been demonstrated in phase I [73] clinical trials that the co-culture of HSCs with mesenchymal stromal cells provides safe condition for transplantation, as well as, increased HSCs expansion rate along with faster Neutrophil and platelet recovery compared to the non-prior co-cultured HSCs [73]. Human fetal liver sinusoidal endothelial cells are the other cells used for HSC expansion in co-culture systems which are engineered to express adenoviral E4 or F1 genes (hFLSECs-E4orF1). Huilin et al. [74] demonstrated that co-culture of umbilical cord blood CD34<sup>+</sup> HSCs with hFLSECs-E4orF1 culminates with 3.15-fold increase in expansion of CD34<sup>+</sup> cells compared to control group. Yi Lou et al. [75] also reported the role of macrophages in fate determination of HSCs. M2 macrophages co-culture with umbilical cord blood CD34<sup>+</sup> HSCs has resulted in 3.8-fold increase in the number of CD34<sup>+</sup> cells compared to control group.

Osteoblasts-derived MSCs are also implemented in co-culture systems for expansion of hematopoietic stem cells. Mathew et al. [76] indicated that M-OST cells co-culture with CD34<sup>+</sup> HSCs, will result in 3.7-fold increase in the number of CD34<sup>+</sup> cells. It was also demonstrated that hCB CD34<sup>+</sup> co-culture with M-OST leads to elevated levels of CXCR4 expression in CD34<sup>+</sup> cells compared to control group. This process uses the wnt  $\beta$ -catenin signaling pathway.

Moreover, Kylie Mei Young et al. [77] reported a 6-fold increase in CD34<sup>+</sup> cells number in the 7th day of culture after specific human liver-derived cell population with CD<sub>34</sub><sup>Lo</sup> and CD<sub>133</sub><sup>Lo</sup> surface markers co-culture with CD<sub>133</sub><sup>hi</sup> and CD<sub>34</sub><sup>hi</sup> HSCs, compared to the control group. Furthermore, they demonstrated that FL CD<sub>133</sub><sup>lo</sup> and CD<sub>34</sub><sup>lo</sup> cells increase the CD34<sup>+</sup> HSC number through production of soluble factors like SCF, IGF2, CXCL12, and AngPTLS.

Mkirre gene is the homologue of kirre gene in CP9 cells of mice that support HSCs in mice bone marrow. mkirre downregulation has led to abolished supporting capacity of these cells. Mutiur Rehman khan et al. [78] in a study also transferred mkirre gene, which encodes a type I transmembrane protein, into AFT24 cells and generated AFT24-hkirre cells. Direct co-culture of these cells with HSCs showed an almost 2.5 fold increase of CD34<sup>+</sup>CD38<sup>-</sup> cells number in comparison to the control group Table 1.

### 7.2. Notch ligands

Notch signaling cascade is considered as an important pathway in lymphopoiesis and HSCs fate determination [79]. This pathway imposes positive effects on HSCs self-renewal under stressed

hematopoiesis, however, no effects have been imposed in steady conditions [8]. Notch ligands include DLL family and Jagged which activate the notch signaling pathway, promoting HSCs ex vivo expansion [80]. Notch ligand related effects in HSCs are dose dependent. The expansion of HSCs in human cord blood is stimulated by Delta 1 under the low dosage condition, while, greater doses of a similar factor induces apoptosis [67].

### 7.3. Wnt signaling and CHIR99021

Wnts are secretory lipoproteins which bind to frizzelle receptors [81]. Wnt signaling plays essential roles in modulating HSCs and keeps them in quiescence phase [82]. Similar to notch ligands, wnt signaling effects are also dose-dependent, so that, HSC expansion is induced in lower doses, while, increased doses result in HSCs exhaustion [83]. Soluble wnts such as wnt3a and wnt5a also elevate HSC activity. It has been reported that LT-HSCs treatment with Wnt5a in ex vivo cultures results in HSC implantation capacity loss [84,85]. In contrast, glycogen synthase kinase 3B (GSK3B) inhibitor treatment, which activates wnt signaling pathway, also induces human HSC engraftment and expansion in xeno-grafted mice [86]. Umbilical cord blood HSCs and osteoblasts-derived MSC co-culture can also culminate the HSCs expansion through wnt and  $\beta$ -catenin signaling pathways, in vitro [87]. CHIR99021 is a GSK3B inhibitor which induces the B glycosidase overexpression and wnt pathway activation along with embryonic stem cell (ESC) self-renewal ability support [88,89]. Hung et al. [89], have also reported that the administration of M-TOR pathway (CHIR99021) and GSK3B (Rapamycin) inhibitors in ex vivo HSCs culture using cytokine free medium, results in LT-HSC functions maintenance. It has also been reported that CHIR99021 and Rapamycin combination provokes cell cycle without apoptosis induction.

### 7.4. Sonic hedgehog (Shh)

Shh protein can impose positive effects on human HSCs proliferation and regeneration in SCID/NOD mice [67]. It has also been indicated that inhibition of GSK3B can modulate certain pathways including shh, which induces elevated regeneration [90]. Shh induced expansion is dependent on BMP4, which is the downstream pathway for shh, and its elimination inhibits such expansion [8]. BMPs are members of transforming growth factor  $\beta$  (TGF $\beta$ ) superfamily that negatively regulate HSCs in mice endosteal niche [91]. Human HSCs via BMP receptors expression improve the HSC maintenance and proliferation [92,93]. A lower dose of TGF $\beta$ 2 has been reported to induce the Lin<sup>-</sup>, sca-1<sup>+</sup> and Kit<sup>+</sup> cells proliferation in C57BL/6 mice [94,95]. According to Nakauchi et al. [85] findings, unmyelinated Schwann cells-derived TGF $\beta$  is necessary for HSCs hibernation maintenance.

### 7.5. Fibroblast growth factor (FGF)

Mice bone marrow analysis has revealed the expression of FGF receptor on every long term mouse bone marrow HSCs [96]. FGF1 and FGF2 supplementation in serum free culture medium of inseparable mice osteoblasts also support the HSCs expansion and regeneration [96–98]. Additionally, FGF receptor derivatives have been used for expansion and survival support of both short and long term HSCs in culture medium [99].

### 7.6. Insuline-like growth factor (IGF) and Parathyroid hormone (PTH)

Cassellia et al. [100] suggested IGF1 as a completely essential factor for osteoblasts-mediated endosteal niche formation. IGF1 gene knock-downing or IGF1 inhibition will prevent endosteal niche formation and HSC engraftment. IGF is also a downstream molecule of PTH which plays important roles in the HSC expansion regulation.

PTH through osteoblasts survival and activation plays an important

**Table 1**  
Various methods used for Human/Murine HSC expansion.

Methods	Effects	Mechanism	Source of HSC	Reference
Co-culture with mesenchymal stromal cell	<ul style="list-style-type: none"> <li>● Homing induction</li> <li>● Self-renewal induction and expansion of HSC</li> </ul>	<ul style="list-style-type: none"> <li>● SDF1 expression</li> <li>● Cell-to-cell interaction, cytokine secretion, wnt and <math>\beta</math>-catenin signaling pathways</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 70,72,73</li> </ul>
Co-culture with hFLECs-E4 or F1	<ul style="list-style-type: none"> <li>● Expansion of the HSC</li> </ul>	<ul style="list-style-type: none"> <li>● Unknown</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 74</li> </ul>
Co-culture with M2 macrophages	<ul style="list-style-type: none"> <li>● Expansion of the HSC</li> </ul>	<ul style="list-style-type: none"> <li>● Unknown</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 75</li> </ul>
Co-culture with M-OST cell	<ul style="list-style-type: none"> <li>● Induction of homing</li> </ul>	<ul style="list-style-type: none"> <li>● Wnt and <math>\beta</math>-catenin signaling pathways</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 76</li> </ul>
Co-culture with FL CD34 <sup>lo</sup> CD133 <sup>lo</sup>	<ul style="list-style-type: none"> <li>● Expansion of the HSC</li> </ul>	<ul style="list-style-type: none"> <li>● expression of CXCR4</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 77</li> </ul>
Co-culture with APT24-hkire cells	<ul style="list-style-type: none"> <li>● Induction of self-renewal</li> </ul>	<ul style="list-style-type: none"> <li>● Production of SCF, IGF2, CXCL12, and AngPTLS.</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 78</li> </ul>
Treatment with Notch ligands	<ul style="list-style-type: none"> <li>● Induction of self-renewal</li> <li>● Positive effects on self-renewal under stress hematopoiesis</li> </ul>	<ul style="list-style-type: none"> <li>● Unknown</li> </ul>	<ul style="list-style-type: none"> <li>● Human bone marrow CD34+ Lin-,CD38-</li> </ul>	<ul style="list-style-type: none"> <li>● 80</li> </ul>
Activation of Wnt signaling	<ul style="list-style-type: none"> <li>● Promoting ex vivo expansion</li> </ul>	<ul style="list-style-type: none"> <li>● Notch signaling pathway</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 0.82,83</li> </ul>
Administration of CHIR99021	<ul style="list-style-type: none"> <li>● Induction of engraftment and expansion</li> <li>● Induction of self-renewal and maintenance of LT-HSC functions</li> </ul>	<ul style="list-style-type: none"> <li>● GSK3B inhibitor treatment</li> <li>● Inhibition of GSK3B and M-TOR pathway</li> </ul>	<ul style="list-style-type: none"> <li>● LSK Cell(Murine)</li> </ul>	<ul style="list-style-type: none"> <li>● 89</li> </ul>
Treatment with SHH	<ul style="list-style-type: none"> <li>● Induction of elevated regeneration</li> </ul>	<ul style="list-style-type: none"> <li>● Inhibition of <math>\beta</math> glucosidase</li> <li>● Modulating of SHH pathway using GSK3B inhibitor through BMP4 pathway</li> </ul>	<ul style="list-style-type: none"> <li>● LSK Cell(Murine)</li> </ul>	<ul style="list-style-type: none"> <li>● 90</li> </ul>
FGF1 and FGF2 supplementation PTH treatment	<ul style="list-style-type: none"> <li>● Expansion of the HSC</li> <li>● Supported expansion and regeneration of HSC</li> <li>● Enhancement of mobilization from bone marrow into peripheral blood</li> </ul>	<ul style="list-style-type: none"> <li>● Unknown</li> </ul>	<ul style="list-style-type: none"> <li>● Human bone marrow CD34+ Lin-, CD38-</li> </ul>	<ul style="list-style-type: none"> <li>● 0.92,93</li> <li>● 96-99</li> <li>● 97,98,103</li> </ul>
Administration of serum free culture systems with certain cytokines and Anti LILRB2	<ul style="list-style-type: none"> <li>● Improved implantation capacity</li> <li>● Induction of homing</li> <li>● Expansion of the HSC</li> </ul>	<ul style="list-style-type: none"> <li>● SDF1 expression on osteoblasts increased levels of cytokines such as IL6, IL11, GM-CSF, and C-kit</li> <li>● Unknown</li> </ul>	<ul style="list-style-type: none"> <li>● LSK Cell(Murine)</li> <li>● LSK Cell(Murine)</li> </ul>	<ul style="list-style-type: none"> <li>● 107</li> </ul>
Treatment with Pleiotrophin	<ul style="list-style-type: none"> <li>● Induction of HSC quiescence phase</li> </ul>	<ul style="list-style-type: none"> <li>● Up-regulation of RAS/MEK signaling</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 110,111</li> </ul>
Treatment with fucosylation enzymes Complement component (C3a)	<ul style="list-style-type: none"> <li>● Induction of homing and engraftment</li> <li>● Induction of homing and engraftment</li> </ul>	<ul style="list-style-type: none"> <li>● Induction of fucosylation levels on selectin ligands</li> <li>● Induction of CXCR4 expression on HSC membrane</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> <li>● Hu CB HSC</li> <li>● Human bone marrow CD34+ Lin-,CD38-</li> </ul>	<ul style="list-style-type: none"> <li>● 116</li> <li>● 117,118</li> </ul>
Valproic acid Garcinol HOXB4 overexpression or direct injection Administration of Valproic acid and neurotrophic factor Administration of Saza and TSA	<ul style="list-style-type: none"> <li>● Induction of HSC expansion</li> <li>● Expansion of the HSC</li> <li>● Expansion of the HSC</li> <li>● Induction of proliferation</li> <li>● Expansion of HSC and induction of self-renewal</li> </ul>	<ul style="list-style-type: none"> <li>● Inhibition of Histone de acetylation</li> <li>● Inhibition of p53 acetylation</li> <li>● Unknown</li> <li>● Epigenetic modification</li> <li>● Inhibition of DNA methyl transferase</li> <li>● Expression of HOXB4, BMI1, and GATA2</li> <li>● Down regulation of mtln4</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> <li>● Hu CB HSC</li> <li>● LSK Cell(Murine)</li> <li>● Hu CB HSC</li> <li>● Human CD34+ HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 121-123</li> <li>● 120</li> <li>● 121</li> <li>● 124</li> <li>● 125,126</li> </ul>
Treatment with PIC C7 administration Administration of Sb203580 Administration of Caspase inhibitors like ZVADFMK and ZLLYFMK	<ul style="list-style-type: none"> <li>● Induction of proliferation</li> <li>● Expansion of the HSC</li> <li>● Expansion of HSC and induction of self-renewal</li> <li>● Expansion of HSC with myeloid cell lineage differentiation</li> </ul>	<ul style="list-style-type: none"> <li>● Unknown</li> <li>● Inhibition of P<sub>38</sub>MAPK pathway</li> <li>● Inhibition of Caspase and Calpain related apoptosis</li> <li>● Induction of BCL-2 expression</li> <li>● Reduction of caspase 3 expression</li> <li>● Copper elimination</li> </ul>	<ul style="list-style-type: none"> <li>● LSK Cell(Murine)</li> <li>● Hu CB HSC</li> <li>● LSK Cell(Murine)</li> <li>● Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 131</li> <li>● 132</li> <li>● 133,134</li> <li>● 150,151</li> </ul>
TEPA administration	<ul style="list-style-type: none"> <li>● Ex vivo increasing expansion of HSC</li> </ul>	<ul style="list-style-type: none"> <li>● Reduction in the activity of cytochrome oxidase</li> </ul>	<ul style="list-style-type: none"> <li>● Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>● 153,154</li> </ul>

(continued on next page)

Table 1 (continued)

Methods	Effects	Mechanism	Source of HSC	Reference
HSC culture in the presence of cytokines and NAM	<ul style="list-style-type: none"> <li>Inhibition of differentiation and improvement of transplantation</li> </ul>	<ul style="list-style-type: none"> <li>Inhibition of SIRT1 and NAD-dependent ribosyl transferases</li> <li>Reduction of p21 expression</li> <li>Inhibition of SIRT1</li> </ul>	<ul style="list-style-type: none"> <li>Hu CB HSC</li> <li>Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>155,156</li> </ul>
EX-527	<ul style="list-style-type: none"> <li>Induction of proliferation and self-renewal</li> </ul>	<ul style="list-style-type: none"> <li>Induction of homing, proliferation, and survival genes expression</li> </ul>	<ul style="list-style-type: none"> <li>Hu CB HSC</li> <li>LSK Cell(Murine)</li> <li>LSK Cell(Murine)</li> </ul>	<ul style="list-style-type: none"> <li>162, 164</li> </ul>
Treatment with PGE2	<ul style="list-style-type: none"> <li>Expansion of HSC and induction of self-renewal</li> </ul>	<ul style="list-style-type: none"> <li>Induction of HOXB4 gene transcription through expression of USFI</li> </ul>	<ul style="list-style-type: none"> <li>Hu CB HSC</li> <li>LSK Cell(Murine)</li> <li>LSK Cell(Murine)</li> </ul>	<ul style="list-style-type: none"> <li>169,170</li> </ul>
Treatment with TPO	<ul style="list-style-type: none"> <li>Expansion of HSC and induction of homing</li> </ul>	<ul style="list-style-type: none"> <li>Induction of CXCR4</li> </ul>	<ul style="list-style-type: none"> <li>Human Mobilized peripheral blood CD 34+ Cells</li> <li>Human CD34+, CD43 + HSC</li> </ul>	<ul style="list-style-type: none"> <li>176,177</li> </ul>
Administration of AHR antagonist (SR1)	<ul style="list-style-type: none"> <li>Expansion of HSC</li> </ul>	<ul style="list-style-type: none"> <li>Unknown</li> </ul>	<ul style="list-style-type: none"> <li>Human CD34+ HSC</li> </ul>	<ul style="list-style-type: none"> <li>179,180</li> </ul>
Co-administration of UMI71 with SR1	<ul style="list-style-type: none"> <li>Enhancement of differentiation of pluripotent stem cells to HSC</li> </ul>	<ul style="list-style-type: none"> <li>Unknown</li> </ul>	<ul style="list-style-type: none"> <li>Human CD34+ HSC</li> </ul>	<ul style="list-style-type: none"> <li>184</li> </ul>
EDAG inhibition	<ul style="list-style-type: none"> <li>Reduction in the numbers of G1 phase HSCs, induction of survival capacity, reduction of apoptosis</li> </ul>	<ul style="list-style-type: none"> <li>Unknown</li> </ul>	<ul style="list-style-type: none"> <li>Human bone marrow CD34+</li> </ul>	<ul style="list-style-type: none"> <li>171</li> </ul>
Administration of NR101	<ul style="list-style-type: none"> <li>Expansion of HSC, improving maintenance of colony forming capacity</li> </ul>	<ul style="list-style-type: none"> <li>Activation of C-MPL downstream signaling pathway</li> </ul>	<ul style="list-style-type: none"> <li>Human bone marrow CD34+</li> <li>Lin-,CD38-</li> <li>LSK Cell(Murine)</li> </ul>	<ul style="list-style-type: none"> <li>185,186</li> </ul>
Inhibition of P18 (INK4C) by XIE18-6, Compound 40, P18in003,P18in011	<ul style="list-style-type: none"> <li>Expansion of HSC and induction of self-renewal maintenance</li> </ul>	<ul style="list-style-type: none"> <li>Inhibition of p18</li> </ul>	<ul style="list-style-type: none"> <li>Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>183,184</li> </ul>
N-Acetyl cysteine	<ul style="list-style-type: none"> <li>Expansion of the HSC</li> <li>Induction of engraftment</li> </ul>	<ul style="list-style-type: none"> <li>Inhibition of P38 MAPK pathway</li> </ul>	<ul style="list-style-type: none"> <li>Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>182</li> </ul>
Anti miRNA15b and anti miRNA219b	<ul style="list-style-type: none"> <li>Expansion of the HSC</li> </ul>	<ul style="list-style-type: none"> <li>Inhibition of mirRNA15b &amp; mirRNA219B</li> </ul>	<ul style="list-style-type: none"> <li>Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>144</li> </ul>
α-Tocopherol	<ul style="list-style-type: none"> <li>Expansion of HSC</li> </ul>	<ul style="list-style-type: none"> <li>Unknown</li> </ul>	<ul style="list-style-type: none"> <li>LSK Cell(Murine)</li> </ul>	<ul style="list-style-type: none"> <li>148,149</li> </ul>
CAEP	<ul style="list-style-type: none"> <li>Expansion of the HSC</li> </ul>	<ul style="list-style-type: none"> <li>Induction of kit-ligand, HIFα,VEGF&amp;SDF-1</li> </ul>	<ul style="list-style-type: none"> <li>Hu CB HSC</li> </ul>	<ul style="list-style-type: none"> <li>143</li> </ul>
Leptin	<ul style="list-style-type: none"> <li>Expansion of HSC</li> </ul>	<ul style="list-style-type: none"> <li>Activation of Jak2</li> </ul>	<ul style="list-style-type: none"> <li>LSK Cell(Murine)</li> </ul>	<ul style="list-style-type: none"> <li>140-142</li> </ul>
10,074-G5	<ul style="list-style-type: none"> <li>Induction of proliferation</li> </ul>	<ul style="list-style-type: none"> <li>Inhibition of C-Myc</li> </ul>	<ul style="list-style-type: none"> <li>LSK Cell(Murine)</li> </ul>	<ul style="list-style-type: none"> <li>139</li> </ul>
L-NIL	<ul style="list-style-type: none"> <li>Expansion of HSC</li> </ul>	<ul style="list-style-type: none"> <li>Inhibition of iNOS</li> </ul>	<ul style="list-style-type: none"> <li>Human CD34+ HSC</li> </ul>	<ul style="list-style-type: none"> <li>137</li> </ul>
Dastinib	<ul style="list-style-type: none"> <li>Induction of proliferation</li> </ul>	<ul style="list-style-type: none"> <li>Inhibition of c-kit signaling</li> </ul>	<ul style="list-style-type: none"> <li>LSK Cell(Murine)</li> </ul>	<ul style="list-style-type: none"> <li>137</li> </ul>

SDF-1: Stromal cell-derived factor 1, Hu CB HSC: Human umbilical cord blood hematopoietic stem cell, hFLSECs-E4 or F1: Human fetal liver sinusoidal endothelial cells which are engineered to express adenoviral E4 or F1 genes, M-OST cell: Osteoblasts-derived MSCs, CXCR4: C-X-C chemokine receptor 4, SCF: Stem cell factor, IGF: Insulin-like growth factor, ANGPTL2: C-X-C chemokine ligand - 12, GSK3B inhibitor: glycogen synthase kinase 3B inhibitor, LSK-Cell: Lin-Sca-1 + c-Kit + HSC, BMP4: Bone morphogenic protein 4, Shh: Sonic hedge hog, FGF: Fibroblast growth factor, PTH: Parathyroid hormone HOX-B4: Homeobox protein Hox-B4, 5AZA&TSA: 5-aza-2-deoxycytidine and trichostatin, BMI-1: B cell-specific Moloney murine leukemia virus integration site 1, PI-C: Polycitidylic acid, Mtn 4: Matriline 4, SD203580: small molecule inhibitor of P38 MAPK, P38 MAPK: P38 mitogen-activated protein kinase, BCL-2: B-cell lymphoma 2, TEAP: Tetra ethylene pentamin NAM; Nicotine amid, SIRT1: Sirtuin 1, PGE2: Prostaglandin E2, TPO: Thrombopoietin, AHR: Aryl Hydrocarbon receptor, SR1: Stem regemin 1, EDAG: Erythroid differentiation associated gen, C-MPL: myeloproliferative leukemia protein, CAPE: Cafeic Acid phenethyl ester, C7: Imidazole analogue, 10,074-G5: C-myc inhibitor, iNOS: Inducible nitric oxide synthase.

role in calcium hemostasis and bone remodeling regulation [101]. PTH exerts its signaling effects through PTHrPR receptors on osteoblasts [102]. It has been shown that mice treatment with PTH results in HSC mobilization enhancement from bone marrow into peripheral blood. Adams et al. [92] have reported that PTH treatment along with cyclophosphamide chemotherapy protects mice HSCs. Additionally, PTH administration for six weeks after implantation can improve HSCs implantation capacity. Furthermore, Jung et al. [93] have also shown that SDF1 is increasingly expressed on osteoblasts following PTH injection and improves HSC homing [103]. Administration of exogenous PTH also contributes to the elevation of certain cytokines levels such as IL6, IL11, GM-CSF, and C-kit, which are essential in HSC proliferation and differentiation [101].

### 7.7. Angiopoietin-like proteins (ANGPTLs)

ANGPTLs include intensively glycosylated secretory proteins which play significant roles in inflammation, cancer, metabolism, and hematopoiesis [104]. Different ANGPTLs are involved in HSCs expansion stimulation in mice bone marrow [66,67,105]. Akhter et al. [95] have indicated that ANGPTLs 1, 2, 3, 4, 6, and 7 are essential in expansion and survival of mice HSCs. Recent data also indicated that LILRB2 acts as receptor for multiple ANGPTLs. ANGPTL2 by binding to LILRB2, induces notch signaling pathway activation of which ultimately activates MYC gene expression [106]. Considering these data, serum free culture systems including certain cytokines and Anti LILRB2 have been designed to improve the expansion of human umbilical cord HSCs by 5 fold after 10 subcultures [107].

### 7.8. Pleiotrophin

Pleiotrophin is encoded by PTN gene on 7q33 chromosome and is known as Heparin-Binding Brain Mitogen (HBBM) or neurite growth-promoting factor 1 [108]. It is expressed in central and peripheral nerve system, lungs, kidney, gut, and bones [109]. It is also expressed by sinusoidal endothelial cells in bone marrow and improves the survival rate of radiated mice and expansion of LT-HSCs in mice bone marrow and human umbilical cord blood [110,111]. The pleiotrophin-related HSCs quiescence is mainly depended on RAS oncogenes expression. Following pleiotrophin-mediated RAS/MEK signaling activation, DMTF1 transcription factor is activated and increases the HSC quiescence phase [111].

### 7.9. Fucosylation enzymes

One of the important strategies for the improvement of human HSC homing and engraftment is to increase fucosylation levels in selectin ligands expressed on HSC membrane [112]. These ligands are fucosylated by  $\alpha 1 \rightarrow 3$  fucosyltransferase, so that insufficient  $\alpha 1 \rightarrow 3$  fucosylation contributes to lower attachment capacity to P-selectin and E-selectin and ultimately decreased human HSC homing following transplantation [113]. Administration of guanosine diphosphate fucose and fucosyltransferase VI and VII can improve fucosylation levels on selectin ligands and enhance  $CD_{34}^+$  engraftment and homing [113,114]. According to Jay Myers et al. [115], HSCs lack homing and self-renewal abilities in fucosyl transferase deficient mice. Atashi et al. [116] also reported that treatment of  $CD_{133}^+$  umbilical cord blood HSCs with fucosyltransferase VI in protein coated nanoscaffold medium, contributes to elevated expression of CXCR4, VLA4, VLA5, LFA1, and E-cadherin on HSC surface.

### 7.10. Complement components

C3a, as a member of complement component, can improve the CXCR4 expression on HSC membrane by bonding to Hematopoietic stem and progenitor cell and induces HSCs enhanced homing and

engraftment in bone marrow niche [117]. Nie et al. [105] demonstrated that CXCR4 signaling is vital for HSC quiescence phase maintenance and the use of CXCL12 inhibitor in culture medium can promote HSCs entrance to cell cycle and proliferation. C3a-C3aR signaling pathway influences the SDF1-related homing process by improved response to SDF1, binding to VCAM1, expression and secretion of matrix metalloproteinase 9 and migration via sub-endothelial membrane [117,118].

### 7.11. Epigenetic modifiers

Various studies have demonstrated epigenetic effects on self-renewal and differentiation of HSCs. Elizalde et al. [119] have suggested histone deacetylase 3 as an important factor in HSC expansion, so that its inhibition leads to increased expansion in vitro. Nishino et al. [120] have also reported that Garcinol, as a nonspecific inhibitor of histone acetyl transferase, restrains P53 acetylation on lysine 382 (K382), causing the elevated expansion levels of human umbilical cord blood HSCs. Additionally, histone deacetylase inhibition by Valproic acid leads to enhanced expression of CD90, CD117, CD49F, CXCR4 and HOXB4 on HSCs, as well as aldehyde dehydrogenase increased activity, resulting in improved HSCs ex vivo homing and expansion [121–123]. Akin et al. [124] have demonstrated that implementation of epigenetic modifiers such as valproic acid and neurotrophic factor will result in increased umbilical cord blood HSC proliferation.

In adult population, HSCs are usually in quiescent phase and their activation is very crucial for cell division. Araki et al. [125] have used 5aza-2deoxycytidine and trichostatin A (5aza/TSA) as chromatin remodeling agents in culture mediums. Data revealed the 12-fold increase in  $CD_{34}^+$  and  $CD_{38}^-$  HSCs expansion following 5aza/TSA treatment. Additionally, the genes involved in self-renewal process including HOXB4, BMI1, and GATA2 were overexpressed and the expression of cell cycle genes including C-MYC were down-regulated after this treatment [126].

Gene expression analysis in mice and human bone marrow HSCs has also revealed the HOXB expression in mice and human primary HSCs [127]. Furthermore, HOXB4 overexpression or direct injection of HOXB4 contributes to HSCs improved expansion both in vivo and ex vivo [128].

G9a and GLP are strictly conserved lysine methyltransferases which play important roles in gene expression and chromosome structures and can inhibit gene transcription via lysine 9 methylation on histone 3. Unc0638 is a small molecule inhibitor of G9a/GLP. Xioa Chen et al. [129] showed that treatment with unc0638 will increase the bone marrow derived  $CD_{34}CD_{38}^{Lo}$  HSCs expansion rate up to 3-folds.

### 7.12. Matrilins and polycytidylic acid (PI:C)

Matrilins, including matrilin 1, 2, 3, and 4 are oligomeric adaptor proteins in extracellular matrix. Matrilin 4 (mtn4) is expressed in HSCs that are in quiescence phase and prevents further HSC proliferation [130]. It has been shown that the lack of mtn4 due to decreased expression of CXCR4 in HSCs, leads to the increased engraftment capacity, mobilization, and faster and better recovery of blood cells. Hannah Uckelmann et al. [131] have also indicated that mice treatment with PI-C induces an intensive IFN $\alpha$  reaction and down-regulates the mtn4 expression on HSC surface by IFN $\alpha$ , leading to increased HSC proliferation.

### 7.13. C7 and SB203580

C7 is a small imidazole analogue molecule with the 383.12 g/mol molecular weight [131]. Sudipto BARI et al. [132] reported that C7 can improve the expansion of umbilical cord blood HSCs [1] by  $CD_{28}^-$ ,  $CD_{24}^+$ ,  $CD_{49}^{F^-}$ ,  $CD_{90}^+$ , and  $CD_{45}R_A$ -CD markers and [2] by  $CD_{90}^+$ ,  $CD_{45}R_A^-$ ,  $CD_{38}^-$ , and  $CD_{49}F^+D_{34}^+$  CD markers by 4 to 5 fold in comparison to the control group.

Furthermore, Sb203580 is another small molecule inhibitor of P<sub>38</sub>MAPK pathway with the molecular weight of 377.43 g/mol [110]. P38MAPK pathway in response to ROS induces oxidative stress and causes decreased lifespan and self-renewal capability of HSPCs, however, its effects can be limited by P<sub>38</sub>MAPK inhibitors [133,134]. Young Wang et al. [135] have illustrated that c-kit<sup>+</sup>, Lin<sup>-</sup>, and Scf<sup>+</sup> (LKS<sup>+</sup> cell) derived from murine bone marrow, can increase the expansion and self-renewal properties of these cells in the presence of Sb203580, in vitro.

#### 7.14. Dastinib

Dastinib is a second generation tyrosine kinase inhibitor which is used in the treatment of CML and ALL with positive Philadelphia chromosome. Dastinib can inhibit certain tyrosine kinases such as C-Kit, PDGFR, PDGFRB [136]. C-Kit is essential for HSCs maintenance in quiescence phase. Johanna M. Duyvestyn et al. [137] have also shown that Dastinib provokes LT-HSCs entrance to cell cycle and raises proliferation through C-Kit signaling inhibition, indicating the role of c-kit signaling pathway in maintaining the hematopoietic stem cell self-renewal capacity.

#### 7.15. Nitric oxide

Nitric oxide is a free radical with limited lifetime, which has three isoforms. Isoform I is Ca<sup>2+</sup> dependent, isoform III is produced by endothelial cells and isoform II or I NOS is not Ca<sup>2+</sup> dependent. Isoform II causes CD<sub>34</sub><sup>+</sup> HSCs increased differentiation in HL60 monocyte cells [138].

Sigrun Reykdal et al. [139] also demonstrated that L-NIL treatment as an inhibitor of iNOS, increases the expansion of CD<sub>34</sub><sup>+</sup> HSCs by 13.4 fold compared to the control group in day 7 of culture. Moreover, it has been shown that L-NIL treatment decreases the apoptosis compared to the control group.

#### 7.16. 10074-G5

C-Myc is the homologue of viral oncogene (V-Myc) in Myelocytomatosis bird retrovirus. C-Myc regulates specific procedures such as proliferation, cell growth, differentiation, angiogenesis, and apoptosis. Esther Baena et al. [140] showed that prenatal C-Myc inactivation results in the accumulation of LSK-CELL in mice bone marrow. They also showed that the inactivation of C-Myc gene leads to increased expression of the P21. Wilson et al. [141] also suggested that C-Myc elimination leads to increased number of Lin<sup>-</sup> hematopoietic stem cells. Additionally, Merve Aksoz et al. [142] indicated that treatment of LSKCD<sub>34</sub><sup>lo</sup> cells with 10,074-G5 as a C-Myc inhibitor, increases cell population by 2-fold compared to the control group. Inhibition of CDKs like P18, P21, P27, and P57 also induces the LSKCD<sub>34</sub><sup>lo</sup> cells entrance into cell cycle and proliferation. Moreover, 10,074-G5 contributes to Varberg effect through the genes involved in glycolysis which plays a crucial role in proliferation.

#### 7.17. Leptin

Leptin is a protein encoded by obesity gene, which controls food and energy usage through different signaling pathways. It is also involved in hematopoiesis. Leptin receptor expression is observed in different hematopoietic organs such as liver, spleen, and bone marrow. Leptin receptor is also presented on mice and human HSCs. Leptin also induces the proliferation of HSCs and myeloid progenitors and has synergistic effects along with stem cell factor (SCF) in HSC proliferation.

Carolec Dias et al. [143] have also suggested that treatment of mice HSCs with LEP5, which is a synthetic fragment of Leptin, leads to 2-fold increase in mice HSC population through JAK2 activation.

#### 7.18. $\alpha$ -Tocopherol

$\alpha$ -Tocopherol is a member of vitamin E family with an important role in cell signaling, inflammation, apoptosis, and cell proliferation. Amanda Nogueira pedro et al. [144] demonstrated that  $\alpha$ -Tocopherol use increases the mice LSK cells up to 2-fold.

#### 7.19. Cafeic Acid phenethyl ester (CAPE)

CAPE is one of the derivatives of honey wax that has anti-oxidant and anti-inflammatory properties [145]. It has been shown that CAPE has a non-competitive inhibitory effect on 5-lipoxygenase enzyme [146]. The findings also suggest that CAPE has anti-metastatic and anti-tumor properties by reducing the production of matrix metalloproteinase x-2 and -9 (MMP) and vascular endothelial growth factor (VEGF) in CT26 cells [147]. Wang et al. [148] proved that CAPE contributes to elevated expression of Kit-Ligand and heme oxygenase-1, both of which have significant roles in the regulation of hematopoietic stem progenitor cells (HSPC) function.

Lui Yimming et al. [148] also reported a 2.5-fold increase in umbilical cord blood HSPCs number after CAPE treatment in comparison to control group through increased expression of Kit LiGand (SCF) and HIF-1 $\alpha$ . Additionally, Xiao fang Chen et al. [149] have shown that CAPE increases the homing of LSK cell by upregulation of HIF-1 $\alpha$ , VEGF-A and stromal-derived cellular factor 1 $\alpha$  (SDF-1 $\alpha$ ).

#### 7.20. ZVADFMK and ZLLYFMK

One of the problems of HSC culture is the Caspase and Calpain related apoptosis which causes transplantation failure. Sangeethav et al. [150] reported that the administration of general Caspase and calpain inhibitors including ZVADFMK and ZLLYFMK in CD<sub>34</sub><sup>+</sup> HSC culture media can result in elevated expansion and differentiation into myeloid cell lineage. These two substances lead to increased expression of anti-apoptotic proteins such as bcl-2, and on the other hand, they induce downregulation of proteins involved in apoptosis, including Caspase 1, Caspase 3, and Fas [151].

#### 7.21. Tetraethylene pentamin (TEPA)

Copper acts as a cofactor of the cytochrome oxidase enzyme, which is the key enzyme in the mitochondrial respiratory chain. Copper deficiency disrupts the ATP production via the citric acid cycle and changes the energy production to the Embden–Meyerhof–Parnas [152]. It has been reported that high amounts of Cu in culture medium leads to enhanced HSCs differentiation. Therefore, administration of TEPA as a copper chelator, eliminates Cu from the HSC expansion supporting medium, ex vivo [153,154]. Peled et al. [153] reported that CD<sub>133</sub><sup>+</sup> HSCs culture in IL6, TPO, SCF, FL, and copper chelator (TEPA) enriched medium Leads to increased number of HSC by 89 fold compared to the control group.

#### 7.22. Sirtuin1 inhibitor

Sirtuin1 is a member of NAD<sup>+</sup> dependent histone deacetylase class III family [155]. Sirtuin1 removes acetyl group from histones and non-histone proteins such as transcription factors [152]. Several studies have shown that Sirtuin1 has a significant role in cellular processes such as inflammation, differentiation, and cell survival [156–159]. Nicotine amide (NAM) is a form of vitamin B3 that prevents HSC differentiation and improves transplantation success [160]. It has been shown that NAM causes a significant increase in homing without changing CXCR4 expression level, indicating the effect of NAM on CXCR4 downstream signaling pathway [155]. NAM also inhibits SIRT1 and NAD-dependent ribosyl transferases [161]. Peled et al. [155] have demonstrated that HSC culture in the presence of cytokines and NAM leads to the elevated

numbers of  $CD_{34}^{+}$  and  $CD_{38}^{-}$  HSCs and reduced number of differentiated  $CD_{11c}^{+}$ ,  $CD_{14}^{+}$ ,  $CD_{11b}^{+}$  cells. They also indicated that EX-527 as a SIRT4 specific inhibitor prevents differentiation of umbilical cord blood HSCs [155].

### 7.23. Prostaglandin E2

Prostaglandin E2 is the most active prostaglandin in mammalian cells which is involved in various processes such as proliferation and apoptosis [162]. Prostaglandin E2 was first discovered as a chemical substance for stem cells support and HSC proliferation and self-renewal induction in Zebra fish [163]. Data have revealed that ex-vivo mice HSC treatment with PGE2 for two hours leads to significant raise in regenerated HSC numbers compared to the control group [164]. This agent also enhances the expression of homing genes (CXCR4), proliferation genes (cyclinD1) and survival genes in umbilical cord blood HSC. The exact action mechanism of PGE2 is still unclear. However, its interaction with wnt- $\beta$ -catenin pathway has been suggested [165]. Data from a phase I clinical trial study on 16 cord blood samples treated with 16-dimethyl prostaglandin E2, have indicated safe and accelerated neutrophil recovery in patients receiving this treatment compared to the control group [166].

### 7.24. Thrombopoietin (TPO) and NR101

Thrombopoietin (TPO), as the primary regulator of platelet production, shares a high degree of importance in HSC biology [167,168]. Either alone or in combination with cytokines such as IL3, FLT3L, and SCF, TPO induces HSC proliferation, in vitro. Keita et al. [169] demonstrated that TPO induces the USF1 expression which is a positive regulator of HOXB4 gene transcription. SCF1 expression contributes to the elevated HOXB4, which in turn leads to improved HSC self-renewal and repopulation. Yagi et al. [170] have also indicated that TPO induces self-renewal and expansion in both LT-HSC and ST-HSC. NR101 is also a C-MPL or thrombopoietin receptor agonist which increases the  $CD_{34}^{+}$  cells proliferation rate [171]. NR101 to bind to the C-MPL transmembrane domain also requires a histidine residue. Additionally, it causes the increased expansion of  $CD_{34}^{+}CD_{38}^{-}$  cells and the maintenance of colony forming capacity of the cells relative to recombinant human TPO. After binding to C-MPL, NR101 induces the activation of C-MPL downstream signaling pathway including JAK2, STAT5, STAT3 [171].

### 7.25. Aryl Hydrocarbon receptor (AHR) antagonist

It has been reported that nearly 70–80% of HSCs are in quiescence status, in normal hematopoiesis (G0 phase) [172]. AHR is a member of BHLB-PAS transcription factor superfamily which includes AHR1, AHR2, AHR receptors and play an important role in destination determining of HSCs [173]. AHR interacts with Rb protein which is a G1 cell cycle regulator. Other genes such as HES1 and C-Myc are also under direct modulation of AHR [174,175]. AHR antagonists increase the HSC expression of superficial CXCR4 which is involved in homing process [176]. Scientists have introduced SR1 as AHR antagonist for optimum HSC expansion. Additionally, Boitano et al. [177] have proposed Stem Regenin 1 as AHR antagonist to induce nearly 50-fold increase of human HSC expansion compared to control group.

### 7.26. UM171

During screening of chemical substances which can increase the HSC expansion, UM171, a Pyrimido-Indol derivative analogue, was discovered. Despite SR1, this component activates AHR signaling pathway [178]. Li et al. [179] reported that UM171 induces HSPCs differentiation from pluripotent stem cells. Furthermore, UM171 co-administration with SR1, has resulted in significant improvement of

cells expansion. UM171 treatment also has yielded about 13-fold increase in LT-HSC compared to the control group [180]. CD201, CD36, PF4, and GYPB are several genes and surface markers that cause increased expression in UM171-treated HSCs [180,181].

### 7.27. Anti-miRNAs

One of the important factors in self renewal maintenance of HSCs is the Sall4 transcription factor. This factor contains zinc finger domain belonging to the spalt1 like protein family, located on chromosome 20 and is expressed in  $CD_{34}^{+}$  HSCs. miRNA15b and miRNA219b are the main inhibitors of this transcription factor. Anti-miRNA15b and anti-miRNA219b administration in HSC cultures has been associated to increased HSC expansion, in vitro [182].

### 7.28. N-Acetyl cysteine

N-Acetyl cysteine molecule is one of the inhibitors of P38 MAPK pathway. Jing Zou et al. [183] indicated that umbilical cord blood  $CD_{133}^{+}$  HSC treatment with N-Acetyl cysteine leads to decreased ROS formation and increased HSC expansion about 14.5-fold, compared to control group. Linping Hu et al. [184] have shown that the amount of reactive oxygen species in NOD/SCID mice bone marrow is high, which results in decreased engraftment of human umbilical cord blood hematopoietic stem cell in the recipient mice. Additionally, N-acetyl-L-cysteine treatment in mice has resulted in decreased ROS and increased hematopoietic stem cell engraftment by 2.3-fold compared to the control group.

### 7.29. P18 inhibitors

Among INK4 protein family, INK4C or P18 has an important role in cell cycle regulation at phase G1. P18 modulates the cell cycle through inhibition of CDK4/6. The essential role of P18 in HSC self-renewal maintenance has also been indicated. Lack of P18 helps HSCs to overcome the exhaustion process while P18 inhibitors can be useful in HSCs expansion increase.

P18 Ino03 and P18 Ino011 are synthetic inhibitors of P18. It has been proved that LSK cell treatment with these inhibitors increases the engraftment capacity after 16 weeks compared to the control group [185]. Moreover, the population of LSK cells treated with P18 Ino03 and P18 Ino011 has been increased by nearly 4-fold in comparison to control group [185].

Compound 40 is another synthetic inhibitor of P18, so that, treatment of mice LT-HSC with this compound has resulted in increased expansion of the cells by 2.61 fold. Furthermore, the umbilical cord blood HSCs population has been increased by 30% after treatment with compound 40 [186].

In Xiang, Qunxie et al. [186] study, treatment of  $CD_{34}^{+}CD_{49f}^{+}$  HSCs with XIE18-6 as a P18 inhibitor for 7 days, showed a 30% increase in HSCs expansion. Moreover, 10% increase in the LT-HSC population with initial phenotype was also observed in comparison to the control group. XIE 18-6 also caused 1.5-fold increase in the number of LT-HSCs and HSPCs after treatment.

### 7.30. Erythroid differentiation-associated gen (EDAG)

EDAG is a multifunctional transcription factor which is expressed in  $CD_{34}^{+}$  HSCs and is involved in cell apoptosis, differentiation, and proliferation [187]. Zhao et al. [188] have reported that EDAG increases the number of umbilical cord blood HSCs in G1 phase. In order to validate this hypothesis, remarkable decrease in G1 phase HSC numbers and notable increase in survival capacity, as well as decreased apoptosis have been observed following EDAG gene knock down.

### 7.31. IGFBP2

As a member of IGFBPs family, IGFBP2 controls the function, distribution, and activity of IGF1 and IGF2 [189]. This protein is expressed in fetus, different adult tissues, and biologic fluids [190]. IGFBP2 has two mechanisms of action: 1) internal IGFBP2 promotes cell survival by binding to integrin, 2) secretive IGFBP2 bind to surface receptors and regulate proliferation and cell mobilization [190–192]. Huynh Et al [193] illustrated that IGFBP2 expressed by mice bone marrow stromal cell, support HSC functions. Moreover, in IGFBP2-null mice, the number and functions of HSCs are limited due to increased and decreased apoptosis and cell cycle, respectively.

## 8. Microfluidic devices

Microfluidic devices are known as micro total analysis system (MTAS) or LaB onchip [194]. Recent developments in microfluidic systems have resulted in on chip culture advancements, because of the limitations of conventional culture methods [195,196]. Certain problems in precise understanding of dynamic cell response in physiologic conditions have resulted in the development of microfluidic systems in cell culture field. These systems are used to facilitate cell feeding and waste discarding.

### 8.1. Type of cell culture

In vitro cell culture depends on the growth control capacity and cell preservation in lab environment [195]. Microfluidic systems provides culture and analysis facilities in micro scales. Compared to conventional cell culture methods, the microfluidic cell culture (MCC), provides benefits such as flexibility of designed equipments, direct link to downstream analytical systems, perfusion culture availability, automation and very small sample amount, and cell numbers [195].

### 8.2. Two-dimensional (2D) culture

In 2D culture methods, cells are cultivated as suspension or adherent. Two types of cells which require fluidic suspensions include mammals blood cells and yeast cells [197]. Therefore, most of the cells should be cultured on a cell layer in order to preserve their important phenotypic features [197].

Of important factors in microfluidic systems that affects cell adhesion to the surface is treatment and coating of the surface with hydrophilic substances; since, primary matters used to produce microfluidic systems like PDMS are hydrophilic and prevent cell adhesion to the surface [198,199]. In order to reduce the hydrophobicity, certain techniques such as ultra violet radiation, laser or oxidation by plasma oxygen are used [198,200]. Implementation of extracellular matrix proteins like collagen, fibronectin, and laminin are other strategies for hydrophobicity reduction [201,202]. These extracellular matrix proteins bind to the PDMS surface by hydrogen or polar bonds.

### 8.3. Three-dimensional (3D) culture

2D cultures cannot fully demonstrate extracellular matrix found in different tissues and organs as an abstract representation of three dimensional cell structure. 3D cultures are much more efficient in providing environment similar to in vivo condition. Microfluidic systems provide spatial control, perfusion merge, and over-control of gradients. Several required substrates for 3D cultures are capability of interaction with microfluidic chips, hydrogel-based and gel free patterns production [203,204]. Hydrogel based pattern is mostly used in 3D cultures. Hydrogels are natural hydrophilic substances which are used in 3D cultures construction in laboratory models [205,206]. Among 3D cultures, vascular models have certain values such as spatial and temporary gradient control, spatial co-culture and perfusion. Thus, they are

suitable for better understanding the in vitro tumor angiogenesis and the effects of environmental factors on this process [207].

Microfluidic systems can strongly describe the effects of physical factors like temperature and pressure on cell behavior [208]. Cellular interactions are achieved based on cell-to-cell interplay or paracrine signaling mechanisms which determines cell phenotype in response to stimuli. Microfluidic systems permits detection of specific signals in single cell scale [196,209].

One of the methods for cell interactions investigation is the co-culture process. In the first step of this process, the cells are separately cultured and then dynamic interactions can be observed. This procedure can be performed in microfluidic systems via several processes such as mixing culture, micro valve, micro gaps, and droplet technology. Functional features and the combination of extracellular matrix can directly affect cell functions including growth, differentiation, death, and cell morphology. Therefore, extracellular matrix is crucial in cell fate determination. Various materials are used in extracellular matrix construction of including natural (like fibrin, hyaluronan, and nectin) or synthetic (polietilenglicol) polymers. Huei wen wu et al. [210]. have successfully implemented microfluidic systems for separation and counting of umbilical cord blood HSCs. Stefan siber et al. [211] have also demonstrated that after four weeks of HSC culture in microfluidic 3D medium,  $CD_{28}^{-}$  and  $CD_{34}^{+}$  cells construct almost 31% of the whole cell population. On the other hand, it has been revealed that CFU-G, CFU-M and less prevalent CFU-GEMM population is increased in 3D culture medium after 4 weeks, compared to their initial numbers.

## 9. Conclusion

The critical aims in HSC expansion include 1) increase of umbilical cord blood HSCs number for transplantation, 2) decrease of neutrophil and platelet recovery period after transplantation, 3) transplantation improvement without the risk of GVHD, and 4) cost effectiveness of the technique. Since, HSCs can be drawn into various fates such as differentiation, self-renewal, apoptosis, and migration, we have to understand HSC interplay with the other cells and in vivo extracellular matrix. HSCs usually have tendency toward differentiation and apoptosis in culture medium and in order to overcome this problem certain components are currently being used to increase the self-renewal capacity and decrease apoptosis and differentiation rates.

## Acknowledgements

This work has been done as part of the M.Sc. thesis for Mehdi Derakhshani. This study was supported by Stem Cell Research Center at Tabriz University of Medical Sciences, Iran [Grant No 61897]

## References

- [1] D. Lucas, C. Scheiermann, A. Chow, Y. Kunisaki, I. Bruns, C. Barrick, et al., Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration, *Nat. Med.* 19 (6) (2013) 695.
- [2] E.M. Pietras, R. Lakshminarasimhan, J.-M. Techner, S. Fong, J. Flach, M. Binnewies, et al., Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons, *J. Exp. Med.* 211 (2) (2014) 245–262.
- [3] L.D. Wang, A.J. Wagers, Dynamic niches in the origination and differentiation of haematopoietic stem cells, *Nat. Rev. Mol. Cell Biol.* 12 (10) (2011) 643.
- [4] S. Lympieri, F. Ferraro, D.T. Scadden, The HSC niche concept has turned 31, *Ann. N. Y. Acad. Sci.* 1192 (1) (2010) 12–18.
- [5] Y. Sonoda, Immunophenotype and functional characteristics of human primitive CD34-negative hematopoietic stem cells: the significance of the intra-bone marrow injection, *J. Autoimmun.* 30 (3) (2008) 136–144.
- [6] A.W. Wognum, A.C. Eaves, T.E. Thomas, Identification and isolation of hematopoietic stem cells, *Arch. Med. Res.* 34 (6) (2003) 461–475.
- [7] A. Behzad-Behbahani, R. Pouransari, S. Tabei, M. Rahiminejad, M. Robati, R. Yaghobi, et al. (Eds.), Risk of Viral Transmission Via Bone Marrow Progenitor Cells Versus Umbilical Cord Blood Hematopoietic Stem Cells in Bone Marrow Transplantation, *Transplantation Proceedings*, Elsevier, 2005.
- [8] A. Dahlberg, C. Delaney, I.D. Bernstein, Ex vivo expansion of human hematopoietic stem and progenitor cells, *Blood* 117 (23) (2011) 6083–6090.

- [9] E. Csaszar, S. Cohen, P.W. Zandstra, Blood stem cell products: toward sustainable benchmarks for clinical translation, *Bioessays* 35 (3) (2013) 201–210.
- [10] A. Banfi, A. Muraglia, B. Dozin, M. Mastrogiacomo, R. Cancedda, R. Quarto, Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy, *Exp. Hematol.* 28 (6) (2000) 707–715.
- [11] A.J. Friedenstein, J. Gorskaja, N. Kulagina, Fibroblast precursors in normal and irradiated mouse hematopoietic organs, *Exp. Hematol.* 4 (5) (1976) 267–274.
- [12] A.I. Caplan, Mesenchymal stem cells, *J. Orthop. Res.* 9 (5) (1991) 641–650.
- [13] I. Arutyunyan, A. Elchaninov, A. Makarov, T. Fatkhudinov, Umbilical cord as prospective source for mesenchymal stem cell-based therapy, *Stem Cells Int.* 2016 (2016).
- [14] M. Dominici, K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause, et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, *Cytotherapy* 8 (4) (2006) 315–317.
- [15] K.B. DuBose, M. Zayzafoon, J.E. Murphy-Ullrich, Thrombospondin-1 inhibits osteogenic differentiation of human mesenchymal stem cells through latent TGF- $\beta$  activation, *Biochem. Biophys. Res. Commun.* 422 (3) (2012) 488–493.
- [16] D. Belotti, C. Capelli, A. Resovi, M. Introna, G. Taraboletti, Thrombospondin-1 promotes mesenchymal stromal cell functions via TGF $\beta$  and in cooperation with PDGF, *Matrix Biol.* 55 (2016) 106–116.
- [17] S.Y. Jeong, D.H. Kim, J. Ha, H.J. Jin, S.J. Kwon, J.W. Chang, et al., Thrombospondin-2 secreted by human umbilical cord blood-derived mesenchymal stem cells promotes chondrogenic differentiation, *Stem Cells* 31 (10) (2013) 2136–2148.
- [18] K.D. Hankenson, P. Bornstein, The secreted protein thrombospondin 2 is an autocrine inhibitor of marrow stromal cell proliferation, *J. Bone Miner. Res.* 17 (3) (2002) 415–425.
- [19] T. Ponomaryov, A. Peled, I. Petit, R.S. Taichman, L. Habler, J. Sandbank, et al., Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function, *J. Clin. Invest.* 106 (11) (2000) 1331–1339.
- [20] A. Peled, I. Petit, O. Kollet, M. Magid, T. Ponomaryov, T. Byk, et al., Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4, *Science* 283 (5403) (1999) 845–848.
- [21] R.J. Deans, A.B. Moseley, Mesenchymal stem cells: biology and potential clinical uses, *Exp. Hematol.* 28 (8) (2000) 875–884.
- [22] M. Honzczarenko, Y. Le, M. Swierkowski, I. Ghiran, A.M. Glodek, L.E. Silberstein, Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors, *Stem Cells* 24 (4) (2006) 1030–1041.
- [23] S. Robinson, T. Niu, de Lima Ma, J. Ng, H. Yang, J. McMannis, et al., Ex vivo expansion of umbilical cord blood, *Cytotherapy* 7 (3) (2005) 243–250.
- [24] W.A. Noort, A.B. Kruisselbrink, P.S. in't Anker, M. Kruger, R.L. van Bezooijen, R.A. de Paus, et al., Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34+ cells in NOD/SCID mice, *Exp. Hematol.* 30 (8) (2002) 870–878.
- [25] K. Le Blanc, I. Rasmusson, B. Sundberg, C. Götherström, M. Hassan, M. Uzunel, et al., Treatment of severe acute graft-versus-host disease with third party haplo-identical mesenchymal stem cells, *Lancet* 363 (9419) (2004) 1439–1441.
- [26] D.E. Discher, D.J. Mooney, P.W. Zandstra, Growth factors, matrices, and forces combine and control stem cells, *Science* 324 (5935) (2009) 1673–1677.
- [27] S.J. Morrison, D.T. Scadden, The bone marrow niche for hematopoietic stem cells, *Nature* 505 (7483) (2014) 327.
- [28] L. Adamo, O. Naveiras, P.L. Wenzel, S. McKinney-Freeman, J. Mack, J. Gracia-sanchez, et al., Biomechanical forces promote embryonic hematopoiesis, *Nature* 459 (2009) U1131-consis consisflu-U1120.
- [29] J.-W. Shin, A. Buxboim, K.R. Spinler, J. Swift, D.A. Christian, C.A. Hunter, et al., Contractile forces sustain and polarize hematopoiesis from stem and progenitor cells, *Cell Stem Cell* 14 (1) (2014) 81–93.
- [30] M.J. Kiel, Ö.H. Yilmaz, T. Iwashita, O.H. Yilmaz, C. Terhorst, S.J. Morrison, SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells, *Cell* 121 (7) (2005) 1109–1121.
- [31] Y. Omatsu, T. Sugiyama, H. Kohara, G. Kondoh, N. Fujii, K. Kohno, et al., The essential functions of adipo-osteogenic progenitors at the hematopoietic stem and progenitor cell niche, *Immunity* 33 (3) (2010) 387–399.
- [32] S. Méndez-Ferrer, T.V. Michurina, F. Ferraro, A.R. Mazloom, B.D. MacArthur, S.A. Lira, et al., Mesenchymal and hematopoietic stem cells form a unique bone marrow niche, *Nature* 466 (7308) (2010) 829.
- [33] Y. Katayama, M. Battista, W.-M. Kao, A. Hidalgo, A.J. Peired, S.A. Thomas, et al., Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow, *Cell* 124 (2) (2006) 407–421.
- [34] S. Méndez-Ferrer, D. Lucas, M. Battista, P.S. Frenette, Hematopoietic stem cell release is regulated by circadian oscillations, *Nature* 452 (7186) (2008) 442.
- [35] D.J. Nolan, M. Ginsberg, E. Israely, B. Palikou, M.G. Poulos, D. James, et al., Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration, *Dev. Cell* 26 (2) (2013) 204–219.
- [36] H. Kobayashi, J.M. Butler, R. O'donnell, M. Kobayashi, B.-S. Ding, B. Bonner, et al., Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of hematopoietic stem cells, *Nat. Cell Biol.* 12 (11) (2010) 1046.
- [37] D.S. Krause, D.T. Scadden, F.I. Pfeffer, The hematopoietic stem cell niche—home for friend and foe? *Cytometry B Clin. Cytom.* 84 (1) (2013) 7–20.
- [38] M. Kennedy, M. Firpo, K. Choi, C. Wall, S. Robertson, N. Kabrun, et al., A common precursor for primitive erythropoiesis and definitive hematopoiesis, *Nature* 386 (6624) (1997) 488.
- [39] F. Shalaby, J. Rossant, T.P. Yamaguchi, M. Gertsenstein, X.-F. Wu, M.L. Breitman, et al., Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice, *Nature* 376 (6535) (1995) 62.
- [40] W. Li, S.A. Johnson, W.C. Shelley, M.C. Yoder, Hematopoietic stem cell repopulating ability can be maintained in vitro by some primary endothelial cells, *Exp. Hematol.* 32 (12) (2004) 1226–1237.
- [41] P.L. Doan, H.A. Himburg, K. Helms, J.L. Russell, E. Fixsen, M. Quarmyne, et al., Epidermal growth factor regulates hematopoietic regeneration after radiation injury, *Nat. Med.* 19 (3) (2013) 295.
- [42] A. Mendelson, P.S. Frenette, Hematopoietic stem cell niche maintenance during homeostasis and regeneration, *Nat. Med.* 20 (8) (2014) 833.
- [43] A. Birbrair, P.S. Frenette, Niche heterogeneity in the bone marrow, *Ann. N. Y. Acad. Sci.* 1370 (1) (2016) 82–96.
- [44] A. Birbrair, O. Delbono, Pericytes are essential for skeletal muscle formation, *Stem Cell Rev.* 11 (4) (2015) 547.
- [45] Y. Kunisaki, I. Bruns, C. Scheiermann, J. Ahmed, S. Pinho, D. Zhang, et al., Arteriolar niches maintain haematopoietic stem cell quiescence, *Nature* 502 (7473) (2013) 637.
- [46] L. Ding, T.L. Saunders, G. Enikolopov, S.J. Morrison, Endothelial and perivascular cells maintain haematopoietic stem cells, *Nature* 481 (7382) (2012) 457.
- [47] Y. Omatsu, M. Seike, T. Sugiyama, T. Kume, T. Nagasawa, Foxc1 is a critical regulator of hematopoietic stem/progenitor cell niche formation, *Nature* 508 (7497) (2014) 536.
- [48] A. Kalinkovich, A. Spiegel, S. Shvitiel, O. Kollet, N. Jordaney, W. Piacibello, et al., Blood-forming stem cells are nervous: direct and indirect regulation of immature human CD34+ cells by the nervous system, *Brain Behav. Immun.* 23 (8) (2009) 1059–1065.
- [49] D. Lucas, M. Battista, P.A. Shi, L. Isola, P.S. Frenette, Mobilized hematopoietic stem cell yield depends on species-specific circadian timing, *Cell Stem Cell* 3 (4) (2008) 364–366.
- [50] S.K. Nilsson, H.M. Johnston, J.A. Coverdale, Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches, *Blood* 97 (8) (2001) 2293–2299.
- [51] J. Zhang, C. Niu, L. Ye, H. Huang, X. He, W.-G. Tong, et al., Identification of the hematopoietic stem cell niche and control of the niche size, *Nature* 425 (6960) (2003) 836.
- [52] L. Calvi, G. Adams, K. Weibrecht, J. Weber, D. Olson, M. Knight, et al., Osteoblastic cells regulate the haematopoietic stem cell niche, *Nature* 425 (6960) (2003) 841.
- [53] K. Fulzele, D.S. Krause, C. Panaroni, V. Saini, K.J. Barry, X. Liu, et al., Myelopoiesis is regulated by osteocytes through Gsa-dependent signaling, *Blood* 121 (6) (2013) 930–939.
- [54] J. Hoggart, Y. Kfoury, D.T. Scadden, Hematopoietic stem cell niche in health and disease, *Annual Review of Pathology: Mechanisms of Disease* 11 (2016) 555–581.
- [55] F. Arai, A. Hirao, M. Ohmura, H. Sato, S. Matsuoka, K. Takubo, et al., Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche, *Cell* 118 (2) (2004) 149–161.
- [56] D. Visnjic, I. Kalajic, G. Gronowicz, H. Aguila, S. Clark, A. Lichtler, et al., Conditional ablation of the osteoblast lineage in Col2.3Atk transgenic mice, *J. Bone Miner. Res.* 16 (12) (2001) 2222–2231.
- [57] H. Takayanagi, Osteoclast biology and bone resorption, *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.* (2018) 46–53.
- [58] A. Mansour, G. Abou-Ezzi, E. Sitnicka, S.E.W. Jacobsen, A. Wakkach, C. Blin-Wakkach, Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow, *J. Exp. Med.* 209 (3) (2012) 537–549.
- [59] E.J. Hagedorn, E.M. Durand, E.M. Fast, L.I. Zon, Getting more for your marrow: boosting hematopoietic stem cell numbers with PGE2, *Exp. Cell Res.* 329 (2) (2014) 220–226.
- [60] M.A. Walasek, R. van Os, G. de Haan, Hematopoietic stem cell expansion: challenges and opportunities, *Ann. N. Y. Acad. Sci.* 1266 (1) (2012) 138–150.
- [61] K.A. Al-Anazi, Autologous hematopoietic stem cell transplantation for multiple myeloma without cryopreservation, *Bone Marrow Research* 2012 (2012) 917361.
- [62] M. Remberger, J. Tórlén, M. Engström, E. Watz, M. Uhlin, et al., Effect of total nucleated and CD34+ cell dose on outcome after allogeneic hematopoietic stem cell transplantation, *Biology of Blood and Marrow Transplantation* 21 (5) (2015) 889–893.
- [63] C.E. Stevens, A. Scaradavou, C. Carrier, C. Carpenter, P. Rubinstein, An empirical analysis of the probability of finding a well matched cord blood unit: implications for a National Cord Blood Inventory, *Am Soc Hematology* 106 (11) (2005).
- [64] R. Aggarwal, J. Lu, V. J Pompili, H. Das, Hematopoietic stem cells: transcriptional regulation, ex vivo expansion and clinical application, *Curr. Mol. Med.* 12 (1) (2012) 34–49.
- [65] X. Huang, M.-R. Lee, S. Cooper, G. Hangoc, K.-S. Hong, H.-M. Chung, et al., Activation of OCT4 enhances ex vivo expansion of human cord blood hematopoietic stem and progenitor cells by regulating HOXB4 expression, *Leukemia* 30 (1) (2016) 144.
- [66] S. Chou, H.F. Lodish, Fetal liver hepatic progenitors are supportive stromal cells for hematopoietic stem cells, *Proc. Natl. Acad. Sci.* 107 (17) (2010) 7799–7804.
- [67] C.C. Zhang, M. Kaba, G. Ge, K. Xie, W. Tong, C. Hug, et al., Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells, *Nat. Med.* 12 (2) (2006) 240.
- [68] J.M. Butler, D.J. Nolan, E.L. Vertes, B. Varnum-Finney, H. Kobayashi, A.T. Hooper, et al., Endothelial cells are essential for the self-renewal and repopulation of notch-dependent hematopoietic stem cells, *Cell Stem Cell* 6 (3) (2010) 251–264.
- [69] I. McNiece, J. Harrington, J. Turney, J. Kellner, E.J. Shpall, Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells, *Cytotherapy* 6 (4) (2004) 311–317.
- [70] S. Robinson, J. Ng, Niu Te, H. Yang, J. McMannis, S. Karandish, et al., Superior ex

- in vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells, *Bone Marrow Transplant*. 37 (4) (2006) 359.
- [71] W. Wagner, C. Roderburg, F. Wein, A. Diehlmann, M. Frankhauser, R. Schubert, et al., Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors, *Stem Cells* 25 (10) (2007) 2638–2647.
- [72] E. Flores-Figueroa, J.J. Montesinos, P. Flores-Guzmán, G. Gutiérrez-Espíndola, R.M. Arana-Trejo, S. Castillo-Medina, et al., Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells, *Leuk. Res.* 32 (9) (2008) 1407–1416.
- [73] M. de Lima, I. McNiece, S.N. Robinson, M. Munsell, M. Eapen, M. Horowitz, et al., Cord-blood engraftment with ex vivo mesenchymal-cell coculture, *N. Engl. J. Med.* 367 (24) (2012) 2305–2315.
- [74] H. Li, H. Pei, X. Xie, S. Wang, Y. Jia, B. Zhang, et al., Liver sinusoidal endothelial cells promote the expansion of human cord blood hematopoietic stem and progenitor cells, *Int. J. Mol. Sci.* 20 (8) (2019) 1985.
- [75] Y. Luo, L. Shao, J. Chang, W. Feng, Y.L. Liu, M.H. Cottler-Fox, et al., M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion, *Blood advances* 2 (8) (2018) 859–870.
- [76] M. Michalicka, G. Boisjoli, S. Jahan, O. Hovey, E. Doxtator, A. Abu-Khader, et al., Human bone marrow mesenchymal stromal cell-derived osteoblasts promote the expansion of hematopoietic progenitors through beta-catenin and notch signaling pathways, *Stem Cells Dev.* 26 (24) (2017) 1735–1748.
- [77] K.S.M. Yong, C.T. Keng, S.Q. Tan, E. Loh, K.T. Chang, T.C. Tan, et al., Human CD34 lo CD133 lo fetal liver cells support the expansion of human CD34 hi CD133 hi hematopoietic stem cells, *Cellular & Molecular Immunology* 13 (5) (2016) 605.
- [78] I. Ali, W. Jiao, Y. Wang, S. Masood, M.Z. Yousaf, A. Javaid, et al., Ex vivo expansion of functional human UCB-HSCs/HPCs by coculture with AFT024-hkrrr cells, *Biomed. Res. Int.* 2014 (2014).
- [79] S. Chiba, Concise review: notch signaling in stem cell systems, *Stem Cells* 24 (11) (2006) 2437–2447.
- [80] D.-M. Tian, L. Liang, X.-C. Zhao, M.-H. Zheng, X.-L. Cao, H.-Y. Qin, et al., Endothelium-targeted delta-like 1 promotes hematopoietic stem cell expansion ex vivo and engraftment in hematopoietic tissues in vivo, *Stem Cell Res.* 11 (2) (2013) 693–706.
- [81] J. Rios-Esteves, B. Haugen, M.D. Resh, Identification of key residues and regions important for porcupine-mediated Wnt acylation, *J. Biol. Chem.* 289 (24) (2014) 17009–17019.
- [82] M.J. Nemeth, D.M. Bodine, Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways, *Cell Res.* 17 (9) (2007) 746.
- [83] T.C. Luis, M. Ghazvini, B. Naber, E. de Haas, J. van Dongen, R. Fodde, et al., Canonical Wnt signaling regulates hematopoiesis in a dosage-dependent fashion, *Exp. Hematol.* 38 (2010) (S95-S).
- [84] K. Willert, J.D. Brown, E. Danenberg, A.W. Duncan, I.L. Weissman, T. Reya, et al., Wnt proteins are lipid-modified and can act as stem cell growth factors, *Nature* 423 (6938) (2003) 448.
- [85] M.J. Nemeth, L. Topol, S.M. Anderson, Y. Yang, D.M. Bodine, Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation, *Proc. Natl. Acad. Sci.* 104 (39) (2007) 15436–15441.
- [86] K.H. Ko, T. Holmes, P. Palladinetti, E. Song, R. Nordon, T.A. O'Brien, et al., GSK-3 $\beta$  inhibition promotes engraftment of ex vivo-expanded hematopoietic stem cells and modulates gene expression, *Stem Cells* 29 (1) (2011) 108–118.
- [87] Y. Zhang, C. Chai, X.-S. Jiang, S.-H. Teoh, K.W. Leong, Co-culture of umbilical cord blood CD34 $^+$  cells with human mesenchymal stem cells, *Tissue Eng.* 12 (8) (2006) 2161–2170.
- [88] Q.-L. Ying, J. Wray, J. Nichols, L. Battle-Morera, B. Doble, J. Woodgett, et al., The ground state of embryonic stem cell self-renewal, *Nature* 453 (7194) (2008) 519.
- [89] J. Huang, M. Nguyen-McCarty, E.O. Hexner, G. Danet-Desnoyers, P.S. Klein, Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways, *Nat. Med.* 18 (12) (2012) 1778.
- [90] J.J. Trowbridge, A. Xenocostas, R.T. Moon, M. Bhatia, Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation, *Nat. Med.* 12 (1) (2006) 89.
- [91] J. Ross, L. Li, Recent advances in understanding extrinsic control of hematopoietic stem cell fate, *Curr. Opin. Hematol.* 13 (4) (2006) 237–242.
- [92] J. Zheng, H. Huynh, C. Zhang, Angiopoietin-like protein 3 supports the activity of mouse hematopoietic stem cells in the bone marrow niche, *Am Soc Hematology* 117 (2) (2009) 1–9.
- [93] G. Bhardwaj, B. Murdoch, D. Wu, D. Baker, K. Williams, K. Chadwick, et al., Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation, *Nat. Immunol.* 2 (2) (2001) 172.
- [94] J.C. Langer, E. Henckaerts, J. Orenstein, H.-W. Snoeck, Quantitative trait analysis reveals transforming growth factor- $\beta$ 2 as a positive regulator of early hematopoietic progenitor and stem cell function, *J. Exp. Med.* 199 (1) (2004) 5–14.
- [95] E. Henckaerts, J.C. Langer, J. Orenstein, H.-W. Snoeck, The positive regulatory effect of TGF- $\beta$ 2 on primitive murine hemopoietic stem and progenitor cells is dependent on age, genetic background, and serum factors, *J. Immunol.* 173 (4) (2004) 2486–2493.
- [96] G. de Haan, E. Weersing, B. Dontje, R. van Os, L.V. Bystrykh, E. Vellenga, et al., In vitro generation of long-term repopulating hematopoietic stem cells by fibroblast growth factor-1, *Dev. Cell* 4 (2) (2003) 241–251.
- [97] J.S. Yeoh, R. van Os, E. Weersing, A. Ausema, B. Dontje, E. Vellenga, et al., Fibroblast growth factor-1 and-2 preserve long-term repopulating ability of hematopoietic stem cells in serum-free cultures, *Stem Cells* 24 (6) (2006) 1564–1572.
- [98] A. Crcareva, T. Saito, A. Kunisato, K. Kumano, T. Suzuki, M. Sakata-Yanagimoto, et al., Hematopoietic stem cells expanded by fibroblast growth factor-1 are excellent targets for retrovirus-mediated gene delivery, *Exp. Hematol.* 33 (12) (2005) 1459–1469.
- [99] M.A. Weinreich, I. Lintmaier, L. Wang, H.D. Liggitt, M.A. Harkey, C.A. Blau, Growth factor receptors as regulators of hematopoiesis, *Blood* 108 (12) (2006) 3713–3721.
- [100] A. Caselli, T.S. Olson, S. Otsuru, X. Chen, T.J. Hofmann, H.D. Nah, et al., IGF-1 mediated osteoblastic niche expansion enhances long-term hematopoietic stem cell engraftment after murine bone marrow transplantation, *Stem Cells* 31 (10) (2013) 2193–2204.
- [101] R. Garrett, S.G. Emerson, The role of parathyroid hormone and insulin-like growth factors in hematopoietic niches: physiology and pharmacology, *Mol. Cell. Endocrinol.* 288 (1–2) (2008) 6–10.
- [102] J.T. Swarthout, R.C. D'Alonzo, N. Selvamurugan, N.C. Partridge, Parathyroid hormone-dependent signaling pathways regulating genes in bone cells, *Gene* 282 (1–2) (2002) 1–17.
- [103] Y. Jung, J. Wang, A. Schneider, Y.-X. Sun, A. Koh-Paige, N. Osman, et al., Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing, *Bone* 38 (4) (2006) 497–508.
- [104] T. Kadomatsu, M. Endo, K. Miyata, Y. Oike, Diverse roles of ANGPTL2 in physiology and pathophysiology, *Trends in Endocrinology & Metabolism* 25 (5) (2014) 245–254.
- [105] C.C. Zhang, H.F. Lodish, Insulin-like growth factor 2 expressed in a novel fetal liver cell population is a growth factor for hematopoietic stem cells, *Blood* 103 (7) (2004) 2513–2521.
- [106] E. Price, S. Boatman, E. Trompouki, S. Satishchandran, C.W. Carspecken, A. Uong, et al., Angiopoietin-like proteins stimulate HSC development through direct interaction with notch, *Am Soc Hematology* 122 (21) (2013) 1–25.
- [107] M. Deng, Z. Lu, J. Zheng, X. Wan, X. Chen, K. Hirayasu, et al., A motif in LILRB2 critical for Angptl2 binding and activation, *Blood* 124 (6) (2014) 924–935.
- [108] Y.-S. Li, P.G. Milner, A.K. Chauhan, M.A. Watson, R.M. Hoffman, C.M. Kodner, et al., Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity, *Science* 250 (4988) (1990) 1690–1694.
- [109] P. Maillieux, J.-M. Vanderwinden, J.-J. Vanderhaeghen, The new growth factor pleiotrophin (HB-GAM) mRNA is selectively present in the meningeothelial cells of human meningiomas, *Neurosci. Lett.* 142 (1) (1992) 31–35.
- [110] H.A. Himburg, J.R. Harris, T. Ito, P. Daher, J.L. Russell, M. Quarmyne, et al., Pleiotrophin regulates the retention and self-renewal of hematopoietic stem cells in the bone marrow vascular niche, *Cell Rep.* 2 (4) (2012) 964–975.
- [111] H.A. Himburg, X. Yan, P.L. Doan, M. Quarmyne, E. Micewicz, W. McBride, et al., Pleiotrophin mediates hematopoietic regeneration via activation of RAS, *J. Clin. Invest.* 124 (11) (2014) 4753–4758.
- [112] J. Xie, C. Zhang, Ex vivo expansion of hematopoietic stem cells, *Sci. China Life Sci.* 58 (9) (2015) 839–853.
- [113] L. Xia, J.M. McDaniel, T. Yago, A. Doeden, R.P. McEver, Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow, *Blood* 104 (10) (2004) 3091–3096.
- [114] X. Wan, H. Sato, H. Miyaji, J.M. McDaniel, Y. Wang, E. Kaneko, et al., Fucosyltransferase VII improves the function of selectin ligands on cord blood hematopoietic stem cells, *Glycobiology* 23 (10) (2013) 1184–1191.
- [115] J. Myers, Y. Huang, L. Wei, Q. Yan, A. Huang, L. Zhou, Fucose-deficient hematopoietic stem cells have decreased self-renewal and aberrant marrow niche occupancy, *Transfusion* 50 (12) (2010) 2660–2669.
- [116] A. Atashi, M. Islami, Y. Mortazavi, M. Soleimani, Homing genes expression in Fucosyltransferase VI-treated umbilical cord blood CD133+ cells which expanded on protein-coated nanoscaffolds, *Mol. Biotechnol.* 60 (7) (2018) 455–467.
- [117] M. Ratajczak, R. Reza, M. Wysoczynski, M. Kucia, J. Baran, D. Allendorf, et al., Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells, *Leukemia* 18 (9) (2004) 1482.
- [118] R. Reza, D. Mastellos, M. Majka, L. Marquez, J. Ratajczak, S. Franchini, et al., Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1, *Blood* 101 (10) (2003) 3784–3793.
- [119] C. Elizalde, J. Fernández-Rueda, J.M. Salcedo, A. Dorronsoro, I. Ferrin, E. Jakobsson, et al., Histone deacetylase 3 modulates the expansion of human hematopoietic stem cells, *Stem Cells Dev.* 21 (14) (2012) 2581–2591.
- [120] T. Nishino, C. Wang, M. Mochizuki-Kashio, M. Osawa, H. Nakauchi, A. Iwama, Ex vivo expansion of human hematopoietic stem cells by ganciclovir, a potent inhibitor of histone acetyltransferase, *PLoS One* 6 (9) (2011) e24298.
- [121] G. Bug, H. Gül, K. Schwarz, H. Pfeifer, M. Kampmann, X. Zheng, et al., Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells, *Cancer Res.* 65 (7) (2005) 2537–2541.
- [122] H.E. Broxmeyer, Inhibiting HDAC for human hematopoietic stem cell expansion, *J. Clin. Invest.* 124 (6) (2014) 2365–2368.
- [123] R. Hoffman, E.J. Benz Jr., L.E. Silberstein, H. Heslop, J. Anastasi, J. Weitz, Hematology: basic principles and practice, Elsevier Health Sciences, 2013.
- [124] H. Akin, P. Yurdakul, G. Aydin, K. Dalva, M. Beksac, Ex vivo expansion of human umbilical cord blood hematopoietic stem cells (HSCs) with Valproic acid (VPA) or neurotrophic factor (NTF), *Cytotherapy* 19 (5) (2017) S83.
- [125] H. Araki, N. Mahmud, M. Milhem, R. Nunez, M. Xu, C.A. Beam, et al., Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents, *Exp. Hematol.* 34 (2) (2006) 140–149.
- [126] N. Mahmud, B. Petro, S. Baluchamy, X. Li, S. Taioli, D. Lavelle, et al., Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells, *Biology of Blood and Marrow Transplantation* 20 (4) (2014) 480–489.

- [127] C. Abramovich, N. Pineault, H. Ohta, R.K. Humphries, Hox genes: from leukemia to hematopoietic stem cell expansion, *Ann. N. Y. Acad. Sci.* 1044 (1) (2005) 109–116.
- [128] N. Beslu, J. Kros, M. Laurin, N. Mayotte, K.R. Humphries, G. Sauvageau, Molecular interactions involved in HOXB4-induced activation of HSC self-renewal, *Blood* 104 (8) (2004) 2307–2314.
- [129] X. Chen, K. Skutt-Kakaria, J. Davison, Y.-L. Ou, E. Choi, P. Malik, et al., G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment, *Genes Dev.* 26 (22) (2012) 2499–2511.
- [130] F. Deák, R. Wagoner, I. Kiss, M. Paulsson, The matrilins: a novel family of oligomeric extracellular matrix proteins, *Matrix Biol.* 18 (1) (1999) 55–64.
- [131] H. Uckelmann, S. Blaszkiewicz, C. Nicolae, S. Haas, A. Schnell, S. Wurzer, et al., Extracellular matrix protein Matrilin-4 regulates stress-induced HSC proliferation via CXCR4, *J. Exp. Med.* 213 (10) (2016) 1961–1971.
- [132] S. Bari, Q. Zhong, X. Fan, Z. Poon, A.S.T. Lim, T.H. Lim, et al., Ex vivo expansion of SCID-repopulating CD34+ CD90+ CD49f+ hematopoietic stem & progenitor cells from non-enriched human umbilical cord blood with novel azole-based small molecules, *Biology of Blood and Marrow Transplantation* 24 (3) (2018) S189.
- [133] Y. Wang, L. Liu, D. Zhou, Inhibition of p38 MAPK attenuates ionizing radiation-induced hematopoietic cell senescence and residual bone marrow injury, *Radiat. Res.* 176 (6) (2011) 743–752.
- [134] K. Miyamoto, K.Y. Araki, K. Naka, F. Arai, K. Takubo, S. Yamazaki, et al., Foxo3a is essential for maintenance of the hematopoietic stem cell pool, *Cell Stem Cell* 1 (1) (2007) 101–112.
- [135] Y. Wang, J. Kellner, L. Liu, D. Zhou, Inhibition of p38 mitogen-activated protein kinase promotes ex vivo hematopoietic stem cell expansion, *Stem Cells Dev.* 20 (7) (2011) 1143–1152.
- [136] O. Hantschel, F. Grebien, G. Superti-Furga, The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL, *Cancer Res.* 72 (19) (2012) 4890–4895.
- [137] J.M. Duyvestyn, S.J. Taylor, S.A. Daggar, W.Y. Langdon, Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice, *Exp. Hematol.* 44 (5) (2016) 410–421 (e5).
- [138] R. Huber, D. Pietsch, J. Günther, B. Welz, N. Vogt, K. Brand, Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks, *Cell. Mol. Life Sci.* 71 (1) (2014) 63–92.
- [139] S. Reykdal, C. Abboud, J. Liesveld, Effect of nitric oxide production and oxygen tension on progenitor preservation in ex vivo culture, *Exp. Hematol.* 27 (3) (1999) 441–450.
- [140] E. Baena, M. Ortiz, C. Martínez-A, I.M. de Alborán, c-Myc is essential for hematopoietic stem cell differentiation and regulates Lin<sup>−</sup> Sca-1 + c-Kit<sup>−</sup> cell generation through p21, *Exp. Hematol.* 35 (9) (2007) 1333–1343.
- [141] A. Wilson, M.J. Murphy, T. Oskarsson, K. Kaloulis, M.D. Bettess, G.M. Oser, et al., c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation, *Genes Dev.* 18 (22) (2004) 2747–2763.
- [142] M. Aksoz, E. Albayrak, G. Aslan, R. Turan, L. Alyazici, P. Siyah, et al., c-Myc inhibitor 10074-G5 induces murine and human hematopoietic stem and progenitor cell expansion and HDR modulator Rad51 expression, *Curr. Cancer Drug Targets* 19 (6) (2018) 1–61.
- [143] C.C. Dias, A. Nogueira-Pedro, C.M. Barbosa, A.C. Ribeiro-Filho, F. Wasinski, R.C. Araújo, et al., Hematopoietic stem cell expansion caused by a synthetic fragment of leptin, *Peptides* 50 (2013) 24–27.
- [144] A. Nogueira-Pedro, C. Barbosa, H.R.C. Segreto, L. Lungato, V. D’Almeida, A.A.F. Moraes, et al.,  $\alpha$ -Tocopherol induces hematopoietic stem/progenitor cell expansion and ERK1/2-mediated differentiation, *J. Leukoc. Biol.* 90 (6) (2011) 1111–1117.
- [145] J.H. Chen, C.-T. Ho, Antioxidant activities of caffeic acid and its related hydroxycinnamic acid compounds, *J. Agric. Food Chem.* 45 (7) (1997) 2374–2378.
- [146] G. Sud’Ina, O. Mirzoeva, M. Pushkareva, G.A. Korshunova, N. Sumbatyan, S. Varfolomeev, Caffeic acid phenethyl ester as a lipoxygenase inhibitor with antioxidant properties, *FEBS Lett.* 329 (1–2) (1993) 21–24.
- [147] H.-F. Liao, Y.-Y. Chen, J.-J. Liu, M.-L. Hsu, H.-J. Shieh, H.-J. Liao, et al., Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, and metastasis, *J. Agric. Food Chem.* 51 (27) (2003) 7907–7912.
- [148] Y. Liu, B. Zhang, J. Zhang, S. Wang, H. Yao, L. He, et al., CAPE promotes the expansion of human umbilical cord blood-derived hematopoietic stem and progenitor cells in vitro, *Sci. China Life Sci.* 57 (2) (2014) 188–194.
- [149] X. Chen, Y. Han, B. Zhang, Y. Liu, S. Wang, T. Liao, et al., Caffeic acid phenethyl ester promotes hematopoietic stem/progenitor cell homing and engraftment, *Stem Cell Res Ther* 8 (1) (2017) 255.
- [150] V.P. Kale, L.S. Limaye, Expansion of cord blood CD34+ cells in presence of zVADfmk and zLLYfmk improved their in vitro functionality and in vivo engraftment in NOD/SCID mouse, *PLoS One* 5 (8) (2010) e12221.
- [151] Y. Zhang, Y. Gao, Novel chemical attempts at ex vivo hematopoietic stem cell expansion, *Int. J. Hematol.* 103 (5) (2016) 519–529.
- [152] M. Zarrabi, E. Afzal, M. Ebrahimi, Manipulation of hematopoietic stem cell fate by small molecule compounds, *Stem Cells Dev.* 27 (17) (2018) 1175–1190.
- [153] T. Peled, E. Landau, E. Prus, A.J. Treves, E. Fibach, Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34+ cells, *Br. J. Haematol.* 116 (3) (2002) 655–661.
- [154] T. Peled, E. Glukhman, N. Hasson, S. Adi, H. Assor, D. Yudin, et al., Chelatable cellular copper modulates differentiation and self-renewal of cord blood-derived hematopoietic progenitor cells, *Exp. Hematol.* 33 (10) (2005) 1092–1100.
- [155] T. Peled, H. Shoham, D. Aschengrau, D. Yackoubov, G. Frei, N. Rosenheimer, et al., Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment, *Exp. Hematol.* 40 (4) (2012) 342–355 (e1).
- [156] T. Zhang, W.L. Kraus, SIRT1-dependent regulation of chromatin and transcription: linking NAD+ metabolism and signaling to the control of cellular functions, *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics* 1804 (8) (2010) 1666–1675.
- [157] C. Buhrmann, F. Busch, P. Shayan, M. Shakibaei, Sirtuin-1 (SIRT1) is required for promoting chondrogenic differentiation of mesenchymal stem cells, *J. Biol. Chem.* 289 (32) (2014) 22048–22062.
- [158] J. Jang, Y.J. Huh, H.-J. Cho, B. Lee, J. Park, D.-Y. Hwang, et al., SIRT1 enhances the survival of human embryonic stem cells by promoting DNA repair, *Stem Cell Reports* 9 (2) (2017) 629–641.
- [159] H. Yang, Y. Bi, L. Xue, J. Wang, Y. Lu, Z. Zhang, et al., Multifaceted modulation of SIRT1 in cancer and inflammation, *Crit. Rev. Oncog.* 20 (1–2) (2015).
- [160] Berger F, Ramírez-Hernández MaH, Ziegler M. The new life of a centenarian: signalling functions of NAD (P). *Trends Biochem. Sci.* 2004;29(3):111–8.
- [161] C. Krebs, S. Adriouch, F. Braasch, W. Koestner, E.H. Leiter, M. Seman, et al., CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins, *J. Immunol.* 174 (6) (2005) 3298–3305.
- [162] J. Hoggatt, P. Singh, J. Sampath, L.M. Pelus, Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation, *Blood* 113 (22) (2009) 5444–5455.
- [163] S.E. Lyons, N.D. Lawson, L. Lei, P.E. Bennett, B.M. Weinstein, P.P. Liu, A nonsense mutation in zebrafish gata1 causes the bloodless phenotype in vlad tepes, *Proc. Natl. Acad. Sci.* 99 (8) (2002) 5454–5459.
- [164] T.E. North, W. Goessling, C.R. Walkley, C. Lengerke, K.R. Kopani, A.M. Lord, et al., Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis, *Nature* 447 (7147) (2007) 1007.
- [165] W. Goessling, R.S. Allen, X. Guan, P. Jin, N. Uchida, M. Dovey, et al., Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models, *Cell Stem Cell* 8 (4) (2011) 445–458.
- [166] C. Cutler, P. Multani, D. Robbins, H.T. Kim, T. Le, J. Hoggatt, et al., Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation, *Blood* 122 (17) (2013) 3074–3081.
- [167] K. Kaushansky, Thrombopoietin: accumulating evidence for an important biological effect on the hematopoietic stem cell, *Ann. N. Y. Acad. Sci.* 996 (1) (2003) 39–43.
- [168] K. Kaushansky, J.G. Drachman, The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production, *Oncogene* 21 (21) (2002) 3359.
- [169] K. Kirito, N. Fox, K. Kaushansky, Thrombopoietin stimulates Hoxb4 expression: an explanation for the favorable effects of TPO on hematopoietic stem cells, *Blood* 102 (9) (2003) 3172–3178.
- [170] M. Yagi, K.A. Ritchie, E. Sitnicka, C. Storey, G.J. Roth, S. Bartelmez, Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin, *Proc. Natl. Acad. Sci.* 96 (14) (1999) 8126–8131.
- [171] T. Nishino, K. Miyaji, N. Ishiwata, K. Arai, M. Yui, Y. Asai, et al., Ex vivo expansion of human hematopoietic stem cells by a small-molecule agonist of c-MPL, *Exp. Hematol.* 37 (11) (2009) 1364–1377 (e4).
- [172] S.H. Cheshier, S.J. Morrison, X. Liao, L.L. Weissman, In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells, *Proc. Natl. Acad. Sci.* 96 (6) (1999) 3120–3125.
- [173] M.E. Hahn, The aryl hydrocarbon receptor: a comparative perspective, *Comp. Biochem. Physiol. C: Pharmacol. Toxicol. Endocrinol.* 121 (1–3) (1998) 23–53.
- [174] N.-L. Ge, C.J. Elferink, A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein linking dioxin signaling to the cell cycle, *J. Biol. Chem.* 273 (35) (1998) 22708–22713.
- [175] T.A. Gasiewicz, K.P. Singh, F.L. Casado, The aryl hydrocarbon receptor has an important role in the regulation of hematopoiesis: implications for benzene-induced hematopoietic toxicity, *Chem. Biol. Interact.* 184 (1–2) (2010) 246–251.
- [176] K.P. Singh, F.L. Casado, L.A. Opanashuk, T.A. Gasiewicz, The aryl hydrocarbon receptor has a normal function in the regulation of hematopoietic and other stem/progenitor cell populations, *Biochem. Pharmacol.* 77 (4) (2009) 577–587.
- [177] A.E. Boitano, J. Wang, R. Romeo, L.C. Bouchez, A.E. Parker, S.E. Sutton, et al., Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells, *Science* 329 (5997) (2010) 1345–1348.
- [178] I. Fares, J. Chagraoui, Y. Gareau, S. Gingras, R. Ruel, N. Mayotte, et al., Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal, *Science* 345 (6203) (2014) 1509–1512.
- [179] X. Li, C. Xia, T. Wang, L. Liu, Q. Zhao, D. Yang, et al., Pyrimidoindole derivative UM171 enhances derivation of hematopoietic progenitor cells from human pluripotent stem cells, *Stem Cell Res.* 21 (2017) 32–39.
- [180] UM18428 U, UM125454 S. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. *Mortality.* 3:4.
- [181] I. Fares, J. Chagraoui, B. Lehnertz, T. MacRae, N. Mayotte, E. Tomellini, et al., EPCR expression marks UM171-expanded CD34+ cord blood stem cells, *Blood* 129 (25) (2017) 3344–3351.
- [182] M.A. Rahnama, A.A. Movassaghpour, M. Soleimani, A. Atashi, A. Anbarlou, K.S. Asenjan, MicroRNA-15b target Sall4 and diminish in vitro UCB-derived HSCs expansion, *EXCLI J.* 14 (2015) 601.
- [183] J. Zou, P. Zou, J. Wang, L. Li, Y. Wang, D. Zhou, et al., Inhibition of p38 MAPK activity promotes ex vivo expansion of human cord blood hematopoietic stem cells, *Ann. Hematol.* 91 (6) (2012) 813–823.
- [184] L. Hu, H. Cheng, Y. Gao, M. Shi, Y. Liu, Z. Hu, et al., Antioxidant N-acetyl-L-cysteine increases engraftment of human hematopoietic stem cells in immune-deficient mice, *Blood* 124 (20) (2014) (e45–e8).

- [185] Y. Gao, P. Yang, H. Shen, H. Yu, X. Song, L. Zhang, et al., Small-molecule inhibitors targeting INK4 protein p18 INK4C enhance ex vivo expansion of haematopoietic stem cells, *Nat. Commun.* 6 (2015) 6328.
- [186] X.-Q. Xie, P. Yang, Y. Zhang, P. Zhang, L. Wang, Y. Ding, et al., Discovery of novel INK4C small-molecule inhibitors to promote human and murine hematopoietic stem cell ex vivo expansion, *Sci. Rep.* 5 (2015) 18115.
- [187] L.V. Yang, R.H. Nicholson, J. Kaplan, A. Galy, L. Li, Hemogen is a novel nuclear factor specifically expressed in mouse hematopoietic development and its human homologue EDAG maps to chromosome 9q22, a region containing breakpoints of hematological neoplasms, *Mech. Dev.* 104 (1–2) (2001) 105–111.
- [188] K. Zhao, W.-W. Zheng, X.-M. Dong, R.-H. Yin, R. Gao, X. Li, et al., EDAG promotes the expansion and survival of human CD34+ cells, *PLoS One* 13 (1) (2018) e0190794.
- [189] M. Ranke, M. Elmlinger, Functional role of insulin-like growth factor binding proteins, *Hormone Research in Paediatrics* 48 (Suppl. 4) (1997) 9–15.
- [190] B. Schutt, M. Langkamp, U. Rauschnabel, M. Ranke, M. Elmlinger, Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells, *J. Mol. Endocrinol.* 32 (3) (2004) 859–868.
- [191] S.M. Dunlap, J. Celestino, H. Wang, R. Jiang, E.C. Holland, G.N. Fuller, et al., Insulin-like growth factor binding protein 2 promotes glioma development and progression, *Proc. Natl. Acad. Sci.* 104 (28) (2007) 11736–11741.
- [192] A. Hoeflich, R. Reisinger, H. Lahm, W. Kiess, W.F. Blum, H.J. Kolb, et al., Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? *Cancer Res.* 61 (24) (2001) 8601–8610.
- [193] H. Huynh, J. Zheng, M. Umikawa, C. Zhang, R. Silvany, S. Iizuka, et al., IGF binding protein 2 supports the survival and cycling of hematopoietic stem cells, *Blood* 118 (12) (2011) 3236–3243.
- [194] S.C. Terry, J.H. Jerman, J.B. Angell, A gas chromatographic air analyzer fabricated on a silicon wafer, *IEEE transactions on electron devices* 26 (12) (1979) 1880–1886.
- [195] S. Halldorsson, E. Lucumi, R. Gómez-Sjöberg, R.M. Fleming, Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices, *Biosens. Bioelectron.* 63 (2015) 218–231.
- [196] D. Gao, H. Liu, Y. Jiang, J.-M. Lin, Recent developments in microfluidic devices for in vitro cell culture for cell-biology research, *TrAC Trends Anal. Chem.* 35 (2012) 150–164.
- [197] H. Yu, C.M. Alexander, D.J. Beebe, Understanding microchannel culture: parameters involved in soluble factor signaling, *Lab Chip* 7 (6) (2007) 726–730.
- [198] S.L. Peterson, A. McDonald, P.L. Gourley, D.Y. Sasaki, Poly (dimethylsiloxane) thin films as biocompatible coatings for microfluidic devices: cell culture and flow studies with glial cells, *Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials.* 72 (1) (2005) 10–18.
- [199] G. Mehta, M.J. Kiel, J.W. Lee, N. Kotov, J.J. Linderman, S. Takayama, Polyelectrolyte-clay-protein layer films on microfluidic PDMS bioreactor surfaces for primary murine bone marrow culture, *Adv. Funct. Mater.* 17 (15) (2007) 2701–2709.
- [200] C. Zhang, Y. Hu, W. Du, P. Wu, S. Rao, Z. Cai, et al., Optimized holographic femtosecond laser patterning method towards rapid integration of high-quality functional devices in microchannels, *Sci. Rep.* 6 (2016) 33281.
- [201] B.M. Baker, B. Trappmann, S.C. Stapleton, E. Toro, C.S. Chen, Microfluidics embedded within extracellular matrix to define vascular architectures and pattern diffusive gradients, *Lab Chip* 13 (16) (2013) 3246–3252.
- [202] S. Chung, R. Sudo, I.K. Zervantonakis, T. Rimchala, R.D. Kamm, Surface-treatment-induced three-dimensional capillary morphogenesis in a microfluidic platform, *Adv. Mater.* 21 (47) (2009) 4863–4867.
- [203] S.-M. Ong, C. Zhang, Y.-C. Toh, S.H. Kim, H.L. Foo, C.H. Tan, et al., A gel-free 3D microfluidic cell culture system, *Biomaterials* 29 (22) (2008) 3237–3244.
- [204] J. Choi, S. Kim, J. Jung, Y. Lim, K. Kang, S. Park, et al., Wnt5a-mediating neurogenesis of human adipose tissue-derived stem cells in a 3D microfluidic cell culture system, *Biomaterials* 32 (29) (2011) 7013–7022.
- [205] S. Bersini, J.S. Jeon, G. Dubini, C. Arrighini, S. Chung, J.L. Charest, et al., A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone, *Biomaterials* 35 (8) (2014) 2454–2461.
- [206] S. Kim, H. Lee, M. Chung, N.L. Jeon, Engineering of functional, perfusable 3D microvascular networks on a chip, *Lab Chip* 13 (8) (2013) 1489–1500.
- [207] S.M. Weis, D.A. Cheresh, Tumor angiogenesis: molecular pathways and therapeutic targets, *Nat. Med.* 17 (11) (2011) 1359.
- [208] E.W. Young, D.J. Beebe, Fundamentals of microfluidic cell culture in controlled microenvironments, *Chem. Soc. Rev.* 39 (3) (2010) 1036–1048.
- [209] M. Mehling, S. Tay, Microfluidic cell culture, *Curr. Opin. Biotechnol.* 25 (2014) 95–102.
- [210] H.-W. Wu, R.-C. Hsu, C.-C. Lin, S.-M. Hwang, G.-B. Lee, An integrated microfluidic system for isolation, counting, and sorting of hematopoietic stem cells, *Biomicrofluidics* 4 (2) (2010) 024112.
- [211] S. Sieber, L. Wirth, N. Cavak, M. Koenigsmark, U. Marx, R. Lauster, et al., Bone marrow-on-a-chip: long-term culture of human hematopoietic stem cells in a three-dimensional microfluidic environment, *J. Tissue Eng. Regen. Med.* 12 (2) (2018) 479–489.